Registre des drogues innovantes
Nom du contact : Bureau des médicaments brevetés et de la liaison
- Produits pour l'usage humain - Période de protection des données en vigueur
- Produits pour l'usage humain - Période de protection des données terminée
- Produits pour l'usage vétérinaire - Période de protection des données en vigueur
- Produits pour l'usage vétérinaire - Période de protection des données terminée
| Ingrédient(s) médicinal(aux)Footnote 1 | No de la présentation | Drogue innovante | Nom du fabricant | Drogue(s) contenant l'ingrédient médicinal / variante | Date de l'avis de conformité aaaa-mm-jj |
Date de la période de "non-dépôt" de 6 ans |
Prolon- gation pédiat- rique" Oui ou Non |
Fin de la période de protection des données |
|---|---|---|---|---|---|---|---|---|
| abémaciclib | 215268 | Verzenio | Eli Lilly Canada Inc. | S.O. | 2019-04-05 | 2025-04-05 | S.O. | 2027-04-05 |
| abrocitinib | 245854 | Cibinqo | Pfizer Canada ULC | S.O. | 2022-06-29 | 2028-06-29 | Oui | 2030-12-29 |
| acalabrutinib | 214504 | Calquence | AstraZeneca Canada Inc. | Calquence (maléate d'acalabrutinib) | 2019-08-23 | 2025-08-23 | S.O. | 2027-08-23 |
| acétate de léfamuline | 233292 | Xenleta | Sunovion Pharmaceuticals Canada Inc. | S.O. | 2020-07-10 | 2026-07-10 | S.O. | 2028-07-10 |
| acétate de setmélanotide | 268412 | Imcivree | Rhythm Pharmaceuticals, Inc. | S.O. | 2023-05-05 | 2029-05-05 | Oui | 2031-11-05 |
| acide obéticholique | 198418 | Ocaliva | Advanz Pharma Canada Inc. | S.O. | 2017-05-24 | 2023-05-24 | Oui | 2025-11-24 |
| ad26.COV2.S (recombinant) | 253702 | Jcovden | Janssen Inc. | S.O. | 2021-11-23 | 2027-11-23 | S.O. | 2029-11-23 |
| alirocumab | 183116 | Praluent | Sanofi-Aventis Canada Inc. | S.O. | 2016-04-11 | 2022-04-11 | Oui | 2024-10-11 |
| alpélisib | 226941 | Piqray | Novartis Pharmaceuticals Canada Inc. | S.O. | 2020-03-11 | 2026-03-11 | S.O. | 2028-03-11 |
| amifampridine (fourni sous forme de phosphate ď amifampridine) | 232685 | Firdapse | Kye Pharmaceuticals Inc. | S.O. | 2020-07-31 | 2026-07-31 | S.O. | 2028-07-31 |
| amivantamab | 254440 | Rybrevant | Janssen Inc. | S.O. | 2022-03-30 | 2028-03-30 | S.O. | 2030-03-30 |
| andexanet alfa | 266464 | Ondexxya | AstraZeneca Canada Inc. | S.O. | 2023-06-16 | 2029-06-16 | S.O. | 2031-06-16 |
| andusoméran | 275936 | Spikevax XBB.1.5 | Moderna Biopharma Canada Corporation | S.O. | 2023-09-12 | 2029-09-12 | Oui | 2032-03-12 |
| anifrolumab | 246187 | Saphnelo | AstraZeneca Canada Inc. | S.O. | 2021-11-30 | 2027-11-30 | S.O. | 2029-11-30 |
| antigène de surface du virus de l'hépatite B (recombiné) | 259302 | Prehevbrio | VBI Vaccines Inc. | S.O. | 2022-12-06 | 2028-12-06 | S.O. | 2030-12-06 |
| antitoxin botulique équine heptavalent C/ D/ F/ G | 190645 | Bat | Emergent BioSolutions Inc. | S.O. | 2016-12-08 | 2022-12-08 | Oui | 2025-06-08 |
| apalutamide | 211942 | Erleada | Janssen Inc. | S.O. | 2018-07-03 | 2024-07-03 | S.O. | 2026-07-03 |
| asciminib hydrochloride | 255700 | Scemblix | Novartis Pharmaceuticals Canada Inc. | S.O. | 2022-06-23 | 2028-06-23 | S.O. | 2030-06-23 |
| atézolizumab | 196843 | Tecentriq | Hoffmann-La Roche Limited | S.O. | 2017-04-12 | 2023-04-12 | Oui | 2025-10-12 |
| atogépant | 253186 | Qulipta | Abbvie Corporation | S.O. | 2022-12-22 | 2028-12-22 | S.O. | 2030-12-22 |
| avacopan | 248255 | Tavneos | Vifor Fresenius Medical Care Renal Pharma Ltd. | S.O. | 2022-04-14 | 2028-04-14 | S.O. | 2030-04-14 |
| avalglucosidase alfa | 245680 | Nexviazyme | Sanofi-Aventis Canada Inc. | S.O. | 2021-11-12 | 2027-11-12 | Oui | 2030-05-12 |
| avélumab | 204052 | Bavencio | EMD Serono, a Division of EMD Inc., Canada | S.O. | 2017-12-18 | 2023-12-18 | Oui | 2026-06-18 |
| axicabtagène ciloleucel | 218389 | Yescarta | Gilead Sciences Canada Inc. | S.O. | 2019-02-13 | 2025-02-13 | S.O. | 2027-02-13 |
| baloxavir marboxil | 227361 | Xofluza | Hoffmann-La Roche Limited | S.O. | 2020-02-19 | 2026-02-19 | Oui | 2028-08-19 |
| baricitinib | 193687 | Olumiant | Eli Lilly Canada Inc. | S.O. | 2018-08-17 | 2024-08-17 | S.O. | 2026-08-17 |
| belzutifan | 254495 | Welireg | Merck Canada Inc. | S.O. | 2022-07-11 | 2028-07-11 | S.O. | 2030-07-11 |
| benralizumab | 204008 | Fasenra | AstraZeneca Canada Inc. | S.O. | 2018-02-22 | 2024-02-22 | Oui | 2026-08-22 |
| bérotralstat (fourni sous forme de chlorhydrate de bérotralstat) | 252301 | Orladeyo | BioCryst Pharmaceuticals, Inc. | S.O. | 2022-06-02 | 2028-06-02 | Oui | 2030-12-02 |
| besilate de bepotastine | 179294 | Bepreve | Bausch and Lomb Incorporated | S.O. | 2016-07-27 | 2022-07-27 | Oui | 2025-01-27 |
| bictégravir | 203718 | Biktarvy | Gilead Sciences Canada, Inc. | S.O. | 2018-07-10 | 2024-07-10 | OUI | 2027-01-10 |
| bilastine | 184231 | Blexten | Aralez Pharmaceutials Canada Inc. | S.O. | 2016-04-21 | 2022-04-21 | Oui | 2024-10-21 |
| bimékizumab | 238499 | Bimzelx | UCB Canada Inc. | S.O. | 2022-02-14 | 2028-02-14 | S.O. | 2030-02-14 |
| binimetinib | 237410 | Mektovi | Pfizer Canada ULC | S.O. | 2021-03-02 | 2027-03-02 | S.O. | 2029-03-02 |
| bitartrate de cystéamine | 191347 | Procysbi | Horizon Pharma Ireland Ltd. | S.O. | 2017-06-13 | 2023-06-13 | Oui | 2025-12-13 |
| blinatumomab | 181723 | Blincyto | Amgen Canada Incorporated | S.O. | 2015-12-22 | 2021-12-22 | Oui | 2024-06-22 |
| brexpiprazole | 192684 | Rexulti | Otsuka Pharmaceutical Co. Ltd. | S.O. | 2017-02-16 | 2023-02-16 | Oui | 2025-08-16 |
| brexucabtagene autoleucel | 246355 | Tecartus | Gilead Sciences Canada, Inc. | S.O. | 2021-06-08 | 2027-06-08 | S.O. | 2029-06-08 |
| brigatinib | 210369 | Alunbrig | Takeda Canada Incorporated | S.O. | 2018-07-26 | 2024-07-26 | S.O. | 2026-07-26 |
| brivaracétam | 183355 | Brivlera | UCB Canada Incorporated | S.O. | 2016-03-09 | 2022-03-09 | Oui | 2024-09-09 |
| brodalumab | 195317 | Siliq | Bausch Health, Canada Inc. | S.O. | 2018-03-06 | 2024-03-06 | S.O. | 2026-03-06 |
| brolucizumab | 226224 | Beovu | Novartis Pharmaceuticals Canada Inc. | S.O. | 2020-03-12 | 2026-03-12 | S.O | 2028-03-12 |
| burosumab | 216239 | Crysvita | Kyowa Kirin Inc. | S.O. | 2018-12-05 | 2024-12-05 | Oui | 2027-06-05 |
| cabotégravir | 227315 | Cabenuva | ViiV Healthcare ULC | S.O. | 2020-03-18 | 2026-03-18 | Oui | 2028-09-18 |
| cabotégravir de sodium | 227315 | Vocabria | ViiV Healthcare ULC | S.O. | 2020-03-18 | 2026-03-18 | Oui | 2028-09-18 |
| cabozantinib (fourni sous forme de cabozantinib (S) -malate) | 206230 | Cabometyx | Ipsen Biopharmaceuticals Canada Inc. | S.O. | 2018-09-14 | 2024-09-14 | S.O. | 2026-09-14 |
| calaspargase pégol | 268282 | Asparlas | Servier Canada Inc. | S.O. | 2023-11-08 | 2029-11-08 | Oui | 2032-05-08 |
| calcifédiol | 205392 | Rayaldee | Eirgen Pharma Ltd. | S.O. | 2018-07-10 | 2024-07-10 | S.O. | 2026-07-10 |
| cangrélor tétrasodique | 255032 | Kengrexal | Chiesi Farmaceutici S.p.A | S.O. | 2023-01-20 | 2029-01-20 | S.O. | 2031-01-20 |
| capivasertib | 274859 | Truqap | AstraZeneca Canada Inc. | S.O. | 2024-01-26 | 2030-01-26 | S.O. | 2032-01-26 |
| caplacizumab | 230001 | Cablivi | Sanofi-Aventis Canada Inc. | S.O. | 2020-02-28 | 2026-02-28 | S.O. | 2028-02-28 |
| carboxymaltose ferrique | 272960 | Ferinject | Vifor (International) Inc. | S.O. | 2024-03-11 | 2030-03-11 | Oui | 2032-09-11 |
| cédazuridine | 234610 | Inqovi | Otsuka Pharmaceutical Co., Ltd. | S.O. | 2020-07-07 | 2026-07-07 | S.O. | 2028-07-07 |
| cémiplimab | 218718 | Libtayo | Sanofi-Aventis Canada Inc. | S.O. | 2019-04-10 | 2025-04-10 | S.O. | 2027-04-10 |
| cénégermine | 218145 | Oxervate | Dompé farmaceutici S.p.A. | S.O. | 2019-02-08 | 2025-02-08 | S.O. | 2027-02-08 |
| cénobamate | 261689 | Xcopri | Endo Ventures Ltd. | S.O. | 2023-06-12 | 2029-06-12 | S.O. | 2031-06-12 |
| cerliponase alfa | 216539 | Brineura | Biomarin International Limited | S.O. | 2018-12-19 | 2024-12-19 | Oui | 2027-06-19 |
| chAdOx1-S [recombinant] | 253700 | Vaxzevria | AstraZeneca Canada Inc. | S.O. | 2021-11-19 | 2027-11-19 | S.O. | 2029-11-19 |
| chlorhydrate ď ivabradine | 166949 | Lancora | Servier Canada Inc. | S.O. | 2016-12-23 | 2022-12-23 | Oui | 2025-06-23 |
| chlorhydrate d'alectinib | 189442 | Alecensaro | Hoffmann-La Roche Limited | S.O. | 2016-09-29 | 2022-09-29 | S.O. | 2024-09-29 |
| chlorhydrate de capmatinib | 255972 | Tabrecta | Novartis Pharmaceuticals Canada Inc. | S.O. | 2022-05-26 | 2028-05-26 | S.O. | 2030-05-26 |
| chlorhydrate de cariprazine | 249774 | Vraylar | AbbVie Corporation | S.O. | 2022-04-22 | 2028-04-22 | S.O. | 2030-04-22 |
| chlorhydrate de daridorexant | 255507 | Quviviq | Idorsia Pharmaceuticals Ltd. | S.O. | 2023-04-28 | 2029-04-28 | S.O. | 2031-04-28 |
| chlorhydrate de migalastat | 196956 | Galafold | Amicus Therapeutics Canada Inc. | S.O. | 2017-09-05 | 2023-09-05 | Oui | 2026-03-05 |
| chlorhydrate de pitolisant | 238175 | Wakix | Endo Ventures Ltd. | S.O. | 2021-05-25 | 2027-05-25 | Oui | 2029-11-25 |
| chlorhydrate de propivérine | 188323 | Mictoryl / Mictoryl Pediatric | Duchesnay Inc. | S.O. | 2017-01-05 | 2023-01-05 | Oui | 2025-07-05 |
| chlorhydrate de solriamfétol | 237511 | Sunosi | Axsome Malta Ltd. | S.O. | 2021-05-13 | 2027-05-13 | S.O. | 2029-11-13 |
| chlorhydrate de ténapanor | 224850 | Ibsrela | Knight Therapeutics Inc. | S.O. | 2020-04-15 | 2026-04-15 | S.O. | 2028-04-15 |
| chlorhydrate de tipiracil | 205852 | Lonsurf | Taiho Pharma Canada Inc. | S.O. | 2018-01-25 | 2024-01-25 | S.O. | 2026-01-25 |
| chlorhydrate de vernakalant | 190817 | Brinavess | Cipher Pharmaceuticals Inc. | S.O. | 2017-03-13 | 2023-03-13 | S.O. | 2025-03-13 |
| chlorure de maralixibat | 271030 | Livmarli | Mirum Pharmaceuticals, Inc. | S.O. | 2023-07-21 | 2029-07-21 | Oui | 2032-01-21 |
| ciltacabtagene autoleucel | 262122 | Carvykti | Janssen Inc. | S.O. | 2023-02-09 | 2029-02-09 | S.O. | 2031-02-09 |
| clascoterone | 265619 | Winlevi | Sun Pharmaceutical Industries Limited | S.O. | 2023-06-15 | 2029-06-15 | Oui | 2031-12-15 |
| concizumab | 267120 | Alhemo | Novo Nordisk Canada Inc. | S.O. | 2023-03-10 | 2029-03-10 | Oui | 2031-09-10 |
| crisaborole | 206906 | Eucrisa | Pfizer Canada Inc. | S.O. | 2018-06-07 | 2024-06-07 | Oui | 2026-12-07 |
| cyclosilicate de zirconium de sodium | 218799 | Lokelma | AstraZeneca Canada Inc. | S.O. | 2019-07-25 | 2025-07-25 | S.O. | 2027-07-25 |
| daclizumab bêta | 190458 | Zinbryta | Biogen Canada Inc. | S.O. | 2016-12-08 | 2022-12-08 | S.O. | 2024-12-08 |
| dacomitinib | 214572 | Vizimpro | Pfizer Canada Inc. | S.O. | 2019-02-26 | 2025-02-26 | S.O. | 2027-02-26 |
| dalbavancine (fournie sous forme de chlorhydrate de dalbavancine) | 212390 | Xydalba | Endo Ventures Ltd. | S.O. | 2018-09-04 | 2024-09-04 | S.O. | 2026-09-04 |
| daratumumab | 187648 | Darzalex | Janssen Inc. | Darzalex SC | 2016-06-29 | 2022-06-29 | S.O. | 2024-06-29 |
| darolutamide | 226146 | Nubeqa | Bayer Inc. | S.O. | 2020-02-20 | 2026-02-20 | S.O. | 2028-02-20 |
| davésoméran | 267589 | Spikevax Bivalent (Original/Omicron BA.4/5) | Moderna Biopharma Canada Corporation | S.O. | 2022-11-03 | 2028-11-03 | Oui | 2031-05-03 |
| défibrotide sodium | 200808 | Defitelio | Jazz Pharmaceuticals Ireland Limited | S.O. | 2017-07-10 | 2023-07-10 | Oui | 2026-01-10 |
| dérisomaltose ferrique | 193890 | Monoferric | Pharmacosmos A/S | S.O. | 2018-06-22 | 2024-06-22 | S.O. | 2026-06-22 |
| deucravacitinib | 259397 | Sotyktu | Bristol-Myers Squibb Canada | S.O. | 2022-11-24 | 2028-11-24 | S.O. | 2030-11-24 |
| difélikéfaline (fourni sous forme d'acétate de difélikéfaline) |
254548 | Korsuva | Vifor Fresenius Medical Care Renal Pharma Ltd. | S.O. | 2022-08-16 | 2028-08-16 | S.O. | 2030-08-16 |
| dinutuximab | 212066 | Unituxin | United Therapeutics Corporation | S.O. | 2018-11-28 | 2024-11-28 | Oui | 2027-05-28 |
| doravirine | 211293 | Pifeltro | Merck Canada Inc. | Delstrigo | 2018-10-12 | 2024-10-12 | Oui | 2027-04-12 |
| dostarlimab | 251105 | Jemperli | GlaxoSmithKline Inc. | S.O. | 2021-12-23 | 2027-12-23 | S.O. | 2029-12-23 |
| dupilumab | 201285 | Dupixent | Sanofi-Aventis Canada Inc. | S.O. | 2017-11-30 | 2023-11-30 | Oui | 2026-05-30 |
| durvalumab | 202953 | Imfinzi | AstraZeneca Canada Inc. | S.O. | 2017-11-03 | 2023-11-03 | S.O. | 2025-11-03 |
| édaravone | 214391 | Radicava | Mitsubishi Tanabe Pharma Corporation | S.O. | 2018-10-03 | 2024-10-03 | S.O | 2026-10-03 |
| édoxaban | 187363 | Lixiana | Servier Canada Inc. | S.O. | 2016-11-04 | 2022-11-04 | Oui | 2025-05-04 |
| efgartigimod alfa | 267438 | Vyvgart | Argenx BV | S.O. | 2023-09-19 | 2029-09-19 | S.O. | 2031-09-19 |
| elagolix | 209513 | Orilissa | AbbVie Corporation | S.O. | 2018-10-05 | 2024-10-05 | S.O. | 2026-10-05 |
| elasomeran | 252733 | Spikevax | Moderna Biopharma Canada Corporation | Spikevax Bivalent Spikevax Bivalent (Original/Omicron BA.4/5) |
2021-09-16 | 2027-09-16 | Oui | 2030-03-16 |
| elexacaftor | 246955 | Trikafta | Vertex Pharmaceuticals (Canada) Incorporated | S.O. | 2021-06-18 | 2027-06-18 | Oui | 2029-12-18 |
| elotuzumab | 188144 | Empliciti | Bristol-Myers Squibb Canada | S.O. | 2016-06-21 | 2022-06-21 | S.O. | 2024-06-21 |
| elranatamab | 273519 | Elrexfio | Pfizer Canada ULC | S.O. | 2023-12-06 | 2029-12-06 | S.O | 2031-12-06 |
| eluxadoline | 190162 | Viberzi | Allergan Inc. | S.O. | 2017-01-26 | 2023-01-26 | S.O. | 2025-01-26 |
| émicizumab | 212635 | Hemlibra | Hoffmann-La Roche Limited | S.O. | 2018-08-02 | 2024-08-02 | Oui | 2027-02-02 |
| encorafenib | 237413 | Braftovi | Pfizer Canada ULC | S.O. | 2021-03-02 | 2027-03-02 | S.O. | 2029-03-02 |
| enfortumab védotine | 251438 | Padcev | Seagen Inc. | S.O. | 2021-10-29 | 2027-10-29 | S.O. | 2029-10-29 |
| entrectinib | 227517 | Rozlytrek | Hoffmann-La Roche Limited | S.O. | 2020-02-10 | 2026-02-10 | Oui | 2028-08-10 |
| épcoritamab | 271331 | Epkinly | AbbVie Corporation | S.O. | 2023-10-13 | 2029-10-13 | S.O. | 2031-10-13 |
| eptinezumab | 233288 | Vyepti | Lundbeck Canada Inc. | S.O. | 2021-01-11 | 2027-01-11 | S.O. | 2029-01-11 |
| erdafitinib | 224529 | Balversa | Janssen Inc. | S.O. | 2019-10-25 | 2025-10-25 | S.O. | 2027-10-25 |
| érénumab | 208607 | Aimovig | Novartis Pharmaceuticals Canada Inc. | S.O. | 2018-08-01 | 2024-08-01 | S.O. | 2026-08-01 |
| ertugliflozine | 204724 | Steglatro | Merck Canada Inc. | Steglujan Segluromet |
2018-05-09 | 2024-05-09 | S.O. | 2026-05-09 |
| estétrol monohydrate | 236197 | Nextstellis | Searchlight Pharma Inc. | S.O. | 2021-03-05 | 2027-03-05 | S.O. | 2029-03-05 |
| éthyl icosapent | 227235 | Vascepa | HLS Therapeutics Inc. | S.O. | 2019-12-30 | 2025-12-30 | S.O. | 2027-12-30 |
| étranacogène dézaparvovec | 273721 | Hemgenix | CSL Behring Canada Inc. | S.O. | 2023-10-23 | 2029-10-23 | S.O. | 2031-10-23 |
| etrasimod L-arginine | 271038 | Velsipity | Pfizer Canada ULC | S.O. | 2024-01-31 | 2030-01-31 | S.O. | 2032-01-31 |
| évinacumab | 272688 | Evkeeza | Ultragenyx Pharmaceutical Inc. | S.O. | 2023-09-22 | 2029-09-22 | Oui | 2032-03-22 |
| facteur antihémophilique (recombiné), pégylé | 189709 | Adynovate | Takeda Canada Inc. | S.O. | 2016-11-17 | 2022-11-17 | Oui | 2025-05-17 |
| facteur antihémophilique (recombinant pégylé à domaine B tronqué) (aussi connu sous le nom damoctocog alfa pégol) | 210935 | Jivi | Bayer Inc. | S.O. | 2018-10-18 | 2024-10-18 | Oui | 2027-04-18 |
| facteur de coagulation IX (recombinant), pégylé (nonacog beta pegol) | 201114 | Rebinyn | Novo Nordisk Canada Inc. | S.O. | 2017-11-29 | 2023-11-29 | Oui | 2026-05-29 |
| facteur de coagulation IX (recombinant), protéine de fusion d'albumine (rIX-FP) | 180793 | Idelvion | CSL Behring Canada Inc. | S.O. | 2016-01-26 | 2022-01-26 | Oui | 2024-07-26 |
| facteur de von willebrand (recombinant) (vonicog alfa) | 213188 | Vonvendi | Takeda Canada Inc. | S.O. | 2019-01-10 | 2025-01-10 | S.O. | 2027-01-10 |
| facteur VIII antihémophile (recombinant), la chaîne simple (également appelée lonoctocog alfa) | 190891 | Afstyla | CSL Behring Canada Inc. | S.O. | 2016-12-12 | 2022-12-12 | Oui | 2025-06-12 |
| facteur VIII antihémophilique (recombinant, domaine B tronqué), PEGylé (turoctocog alfa pegol) | 218531 | Esperoct | Novo Nordisk Canada Inc. | S.O. | 2019-07-04 | 2025-07-04 | Oui | 2028-01-04 |
| famtozinaméran | 267502 | Comirnaty Original & Omicron BA.4/BA.5 | BioNTech Manufacturing GmbH | S.O. | 2022-10-07 | 2028-10-07 | Oui | 2031-04-07 |
| faricimab | 253904 | Vabysmo | Hoffmann-La Roche Limited | S.O. | 2022-05-27 | 2028-05-27 | S.O. | 2030-05-27 |
| fédratinib (fourni sous forme de chlorhydrate de fédratinib) | 229866 | Inrebic | Bristol-Myers Squibb Canada | S.O. | 2020-07-27 | 2026-07-27 | S.O. | 2028-07-27 |
| fidanacogène élaparvovec | 275853 | Beqvez | Pfizer Canada ULC | S.O. | 2023-12-27 | 2029-12-27 | S.O. | 2031-12-27 |
| filtrat ďantigéne de ľanthrax | 212387 | Biothrax | Emergent Biodefense Operations Lansing LLC | S.O. | 2018-12-13 | 2024-12-13 | S.O. | 2026-12-13 |
| finafloxacin | 172450 | Xtoro | MerLion Pharmaceuticals GmbH | S.O. | 2016-03-11 | 2022-03-11 | Oui | 2024-09-11 |
| finérénone | 258231 | Kerendia | Bayer Inc. | S.O. | 2022-10-14 | 2028-10-14 | S.O. | 2030-10-14 |
| flibansérine | 189352 | Addyi | Searchlight Pharma Inc. | S.O. | 2018-02-27 | 2024-02-27 | S.O. | 2026-02-27 |
| florbetaben (18F) | 193105 | Neuraceq | Isologic Innovative Radiopharmaceuticals Ltd. | S.O. | 2017-02-22 | 2023-02-22 | S.O. | 2025-02-22 |
| follitropine delta | 188743 | Rekovelle | Ferring Inc. | S.O. | 2018-03-22 | 2024-03-22 | S.O. | 2026-03-22 |
| fostamatinib (fourni sous forme de fostamatinib disodique) | 232078 | Tavalisse | Medison Pharma Canada Inc. | S.O. | 2020-11-19 | 2026-11-19 | S.O. | 2028-11-19 |
| fostemsavir (fourni sous forme de fostemsavir trométhamine) | 250213 | Rukobia | ViiV Healthcare ULC | S.O. | 2021-10-01 | 2027-10-01 | S.O. | 2029-10-01 |
| fremanezumab | 226828 | Ajovy | Teva Canada Limited | S.O. | 2020-04-09 | 2026-04-09 | S.O. | 2028-04-09 |
| fumarate de giltéritinib | 227918 | Xospata | Astellas Pharma Canada Inc. | S.O. | 2019-12-23 | 2025-12-23 | S.O. | 2027-12-23 |
| gadotérate de méglumine | 186333 | Dotarem | Guerbet | S.O. | 2016-11-26 | 2022-11-26 | Oui | 2025-05-26 |
| galcanézumab | 219521 | Emgality | Eli Lilly Canada Inc. | S.O. | 2019-07-30 | 2025-07-30 | S.O. | 2027-07-30 |
| gemtuzumab ozogamicine | 223091 | Mylotarg | Pfizer Canada ULC | S.O. | 2019-11-28 | 2025-11-28 | Oui | 2028-05-28 |
| givosiran (fourni sous forme de givosiran sodique) | 237194 | Givlaari | Alnylam Netherlands B.V. | S.O. | 2020-10-09 | 2026-10-09 | S.O. | 2028-10-09 |
| glasdégib | 225793 | Daurismo | Pfizer Canada ULC | S.O. | 2020-04-28 | 2026-04-28 | S.O. | 2028-04-28 |
| glecaprevir, pibrentasvir | 202233 | Maviret | AbbVie Corporation | S.O. | 2017-08-16 | 2023-08-16 | Oui | 2026-02-16 |
| glofitamab | 265517 | Columvi | Hoffmann-La Roche Limited | S.O. | 2023-03-24 | 2029-03-24 | S.O. | 2031-03-24 |
| glycoprotéine E (gE) du virus de la varicelle-zoster | 200244 | Shingrix | GlaxoSmithKline Inc. | S.O. | 2017-10-13 | 2023-10-13 | S.O. | 2025-10-13 |
| guselkumab | 200590 | Tremfya | Janssen Inc. | S.O. | 2017-11-10 | 2023-11-10 | S.O. | 2025-11-10 |
| hémagglutinine recombinée -souche A (H1N1) hémagglutinine recombinée -souche A (H3N2) hémagglutinine recombinée -souche B (VICTORIA) hémagglutinine recombinée -souche B (YAMAGATA) |
235672 | Supemtek | Sanofi Pasteur Limited | S.O. | 2021-01-14 | 2027-01-14 | S.O | 2029-01-14 |
| hemin | 212276 | Panhematin | Recordati Rare Diseases Canada Inc. | S.O. | 2018-07-13 | 2024-07-13 | S.O. | 2026-07-13 |
| hyaluronidase human recombinée | 247727 | Hyqvia | Takeda Canada Inc. | S.O. | 2022-01-14 | 2028-01-14 | Oui | 2030-07-14 |
| idarucizumab | 182503 | Praxbind | Boehringer Ingelheim (Canada) Ltd | S.O. | 2016-04-29 | 2022-04-29 | S.O. | 2024-04-29 |
| idécabtagéne vicleucel | 244266 | Abecma | Celgene Inc. | S.O. | 2021-05-26 | 2027-05-26 | S.O. | 2029-05-26 |
| imelasomeran | 265656 | Spikevax Bivalent | Moderna Biopharma Canada Corporation | S.O. | 2022-09-01 | 2028-09-01 | Oui | 2031-03-01 |
| immune globulines (humaines) de ľ anthrax | 200446 | Anthrasil | Emergent BioSolutions Canada Inc. | S.O. | 2017-11-06 | 2023-11-06 | Oui | 2026-05-06 |
| inclisiran de sodium | 243470 | Leqvio | Novartis Pharmaceuticals Canada Inc. | S.O. | 2021-07-26 | 2027-07-26 | S.O. | 2029-07-26 |
| inébilizumab | 271065 | Uplizna | Horizon Therapeutics Ireland DAC | S.O. | 2023-12-15 | 2029-12-15 | S.O. | 2031-12-15 |
| infigratinib (fourni sous forme de phosphate d'infigratinib) | 246904 | Truseltiq | QED Therapeutics, Inc. | S.O. | 2021-09-27 | 2027-09-27 | S.O. | 2029-09-27 |
| inotuzumab ozogamicine | 204077 | Besponsa | Pfizer Canada Inc. | S.O. | 2018-03-15 | 2024-03-15 | S.O. | 2026-03-15 |
| insulin degludec | 198124 | Tresiba | Novo Nordisk Canada Inc. | Xultophy | 2017-08-25 | 2023-08-25 | Oui | 2026-02-25 |
| insuline icodec | 273850 | Awiqli | Novo Nordisk Canada Inc. | S.O. | 2024-03-12 | 2030-03-12 | S.O. | 2032-03-12 |
| ioflupane (123I) | 201481 | Datscan | GE Healthcare Canada Inc. | S.O. | 2017-12-07 | 2023-12-07 | S.O. | 2025-12-07 |
| isatuximab | 229245 | Sarclisa | Sanofi-Aventis Canada Inc. | S.O. | 2020-04-29 | 2026-04-29 | S.O. | 2028-04-29 |
| isavuconazole (fournie à titre de sulfate isavuconazonium) | 208919 | Cresemba | Avir Pharma Inc. | S.O. | 2018-12-19 | 2024-12-19 | S.O. | 2026-12-19 |
| ixazomib (fourni sous forme de citrate d' ixazomib) | 190498 | Ninlaro | Takeda Canada Inc. | S.O. | 2016-08-04 | 2022-08-04 | S.O. | 2024-08-04 |
| ixékizumab | 184993 | Taltz | Eli Lilly Canada Inc. | S.O. | 2016-05-25 | 2022-05-25 | Oui | 2024-11-25 |
| lanadelumab | 213920 | Takhzyro | Takeda Canada Inc. | S.O. | 2018-09-19 | 2024-09-19 | Oui | 2027-03-19 |
| larotrectinib (fournie à titre de sulfate larotrectinib) | 219998 | Vitrakvi | Bayer Inc. | S.O. | 2019-07-10 | 2025-07-10 | Oui | 2028-01-10 |
| latanoprosténe bunod | 211732 | Vyzulta | Bausch & Lomb Incorporated | S.O. | 2018-12-27 | 2024-12-27 | S.O. | 2026-12-27 |
| lemborexant | 231286 | Dayvigo | Eisai Limited | S.O. | 2020-11-04 | 2026-11-04 | S.O. | 2028-11-04 |
| lénacapavir (fourni sous forme de lénacapavir sodique) | 262999 | Sunlenca | Gilead Sciences Canada, Inc. | S.O. | 2022-11-02 | 2028-11-02 | S.O. | 2030-11-02 |
| létermovir | 204165 | Prevymis | Merck Canada Inc. | S.O. | 2017-11-01 | 2023-11-01 | S.O. | 2025-11-01 |
| lifitegrast | 199810 | Xiidra | Novartis Pharmaceuticals Canada Inc. | S.O. | 2017-12-22 | 2023-12-22 | S.O. | 2025-12-22 |
| lipoprotéine 2086 (rLP2086) recombinante, sous-famille A de neisseria meningitidis groupe B et lipoprotéine 2086 (rLP2086) recombinante, sous-famille B de neisseria meningitidis groupe B | 195550 | Trumenba | Pfizer Canada Inc. | S.O. | 2017-10-05 | 2023-10-05 | Oui | 2026-04-05 |
| lisocabtagene maraleucel | 247562 | Breyanzi | Celgene Inc. | S.O. | 2022-05-06 | 2028-05-06 | S.O. | 2030-05-06 |
| lixisénatide | 193862 | Adlyxine | Sanofi-Aventis Canada Inc. | Soliqua | 2017-05-25 | 2023-05-25 | S.O. | 2025-05-25 |
| lorlatinib | 215733 | Lorbrena | Pfizer Canada ULC | S.O. | 2019-02-22 | 2025-02-22 | S.O. | 2027-02-22 |
| lumacaftor | 181715 | Orkambi | Vertex Pharmaceuticals (Canada) Incorporated | S.O. | 2016-01-26 | 2022-01-26 | Oui | 2024-07-26 |
| lumasiran (fourni sous forme de lumasiran sodique) | 254883 | Oxlumo | Alnylam Netherlands B.V. | S.O. | 2022-03-07 | 2028-03-07 | Oui | 2030-09-07 |
| lurbinectédine | 247485 | Zepzelca | Jazz Pharmaceuticals Ireland Limited | S.O. | 2021-09-29 | 2027-09-29 | S.O. | 2029-09-29 |
| luspatercept | 236441 | Reblozyl | Celgene Inc. | S.O. | 2020-09-25 | 2026-09-25 | S.O. | 2028-09-25 |
| lutetium (177Lu) oxodotreotide | 217184 | Lutathera | Novartis Pharmaceuticals Canada Inc. | S.O. | 2019-01-09 | 2025-01-09 | S.O. | 2027-01-09 |
| lutetium (177Lu) vipivotide tétraxétan | 260951 | Pluvicto | Novartis Pharmaceuticals Canada Inc. | S.O. | 2022-08-25 | 2028-08-25 | S.O. | 2030-08-25 |
| maléate d'avatrombopag | 251688 | Doptelet | Swedish Orphan Biovitrum AB (publ) | S.O. | 2023-11-03 | 2029-11-03 | S.O. | 2031-11-03 |
| maléate de nératinib | 218224 | Nerlynx | Knight Therapeutics Inc. | S.O. | 2019-07-16 | 2025-07-16 | S.O. | 2027-07-16 |
| maribavir | 259676 | Livtencity | Takeda Canada Inc. | S.O. | 2022-09-15 | 2028-09-15 | S.O. | 2030-09-15 |
| mavacamten | 258772 | Camzyos | Bristol-Myers Squibb Canada | S.O. | 2022-11-08 | 2028-11-08 | S.O. | 2030-11-08 |
| mécasermine | 235023 | Increlex | Ipsen Biopharmaceuticals Canada Inc. | S.O. | 2020-12-17 | 2026-12-17 | Oui | 2029-06-17 |
| mépolizumab | 179850 | Nucala | GlaxoSmithKline Inc. | S.O. | 2015-12-03 | 2021-12-03 | Oui | 2024-06-03 |
| mésylate d' énasidénib | 217033 | Idhifa | Celgene Inc. | S.O. | 2019-02-06 | 2025-02-06 | S.O. | 2027-02-06 |
| mésylate de bélumosudil | 245791 | Rezurock | Sanofi-Aventis Canada Inc. | S.O. | 2022-03-23 | 2028-03-23 | S.O. | 2030-03-23 |
| mésylate de lenvatinib | 180877 | Lenvima | Eisai Limited | S.O. | 2015-12-22 | 2021-12-22 | Oui | 2024-06-22 |
| metreleptin | 273908 | Myalepta | Amryt Pharmaceuticals DAC | S.O. | 2024-01-17 | 2030-01-17 | Oui | 2032-07-17 |
| midostaurine | 201101 | Rydapt | Novartis Pharmaceuticals Canada Inc. | S.O. | 2017-07-21 | 2023-07-21 | Oui | 2026-01-21 |
| mirikizumab | 266471 | Omvoh | Eli Lilly Canada Inc. | S.O. | 2023-07-20 | 2029-07-20 | S.O. | 2031-07-20 |
| mogamulizumab | 251277 | Poteligeo | Kyowa Kirin, Inc. | S.O. | 2022-06-02 | 2028-06-02 | S.O. | 2030-06-02 |
| monohydrate de técovirimat | 247561 | Tpoxx | Siga Technologies, Inc. | S.O. | 2021-11-29 | 2027-11-29 | Oui | 2030-05-29 |
| nécitumumab | 193689 | Portrazza | Eli Lilly Canada Inc. | S.O. | 2017-03-16 | 2023-03-16 | S.O. | 2025-03-16 |
| nétupitant | 196495 | Akynzeo | Knight Therapeutics Inc. | S.O. | 2017-09-28 | 2023-09-28 | S.O. | 2025-09-28 |
| niraparib | 216792 | Zejula | GlaxoSmithKline Inc. | Akeega | 2019-06-27 | 2025-06-27 | S.O. | 2027-06-27 |
| nirmatrelvir | 259186 | Paxlovid | Pfizer Canada ULC | S.O. | 2022-01-17 | 2028-01-17 | S.O. | 2030-01-17 |
| nirsevimab | 269388 | Beyfortus | AstraZeneca Canada Inc. | S.O. | 2023-04-19 | 2029-04-19 | Oui | 2031-10-19 |
| nivolumab | 180828 | Opdivo | Bristol-Myers-Squibb Canada | Opdualag | 2015-09-25 | 2021-09-25 | Oui | 2024-03-25 |
| nusinersen | 200070 | Spinraza | Biogen Canada Inc. | S.O. | 2017-06-29 | 2023-06-29 | Oui | 2025-12-29 |
| obiltoxaximab | 230825 | Anthim | Elusys Therapeutics, Inc. | S.O. | 2020-07-30 | 2026-07-30 | S.O. | 2028-07-30 |
| ocrélizumab | 198094 | Ocrevus | Hoffmann-La Roche Limited | S.O. | 2017-08-14 | 2023-08-14 | S.O. | 2025-08-14 |
| odévixibat | 273741 | Bylvay | Medison Pharma Canada Inc. | S.O. | 2023-10-30 | 2029-10-30 | Oui | 2032-04-30 |
| olaparib | 182823 | Lynparza | AstraZeneca Canada Inc. | S.O. | 2016-04-29 | 2022-04-29 | S.O. | 2024-04-29 |
| olaratumab | 203478 | Lartruvo | Eli Lilly Canada Inc. | S.O. | 2017-11-23 | 2023-11-23 | S.O. | 2025-11-23 |
| olipudase alfa | 275236 | Xenpozyme | Sanofi-Aventis Canada Inc. | S.O. | 2024-02-28 | 2030-02-28 | Oui | 2032-08-28 |
| onasemnogéne abéparvovec | 239719 | Zolgensma | Novartis Pharmaceuticals Canada Inc. | S.O. | 2020-12-15 | 2026-12-15 | Oui | 2029-06-15 |
| osimertinib mesylate | 188171 | Tagrisso | AstraZeneca Canada Inc. | S.O. | 2016-07-05 | 2022-07-05 | S.O. | 2024-07-05 |
| ospémiféne | 222001 | Osphena | Duchesnay Inc. | S.O. | 2021-07-16 | 2027-07-16 | S.O. | 2029-07-16 |
| oxyhydroxide sucroferrique | 201492 | Velphoro | Vifor Fresenius Medical Care Renal Pharma Ltd. | S.O. | 2018-01-05 | 2024-01-05 | S.O. | 2026-01-05 |
| ozanimod (fourni sous forme de chlorhydrate d'ozanimod) | 232761 | Zeposia | Bristol-Myers Squibb Canada Co. | S.O. | 2020-10-02 | 2026-10-02 | S.O. | 2028-10-02 |
| ozénoxacine | 192925 | Ozanex | Ferrer Internacional, S.A. | S.O. | 2017-05-01 | 2023-05-01 | Oui | 2025-11-01 |
| palbociclib | 182048 | Ibrance | Pfizer Canada Inc. | S.O. | 2016-03-16 | 2022-03-16 | Oui | 2024-09-16 |
| palovaroténe | 252065 | Sohonos | Ipsen Biopharmaceuticals Canada Inc. | S.O. | 2022-01-21 | 2028-01-21 | Oui | 2030-07-21 |
| particules pseudo-virales (PPV) de la protéine de spicule du sras-cov-2 | 254598 | Covifenz | Medicago Inc. | S.O. | 2022-02-24 | 2028-02-24 | S.O. | 2030-02-24 |
| patiromer sorbitex calcique | 210368 | Veltassa | Vifor Fresenius Medical Care Renal Pharma Ltd. | S.O. | 2018-10-03 | 2024-10-03 | S.O. | 2026-10-03 |
| patisiran (sous forme de patisiran sodique) | 221896 | Onpattro | Alnylam Netherlands B.V. | S.O. | 2019-06-07 | 2025-06-07 | S.O. | 2027-06-07 |
| pegcétacoplan | 263432 | Empaveli | Swedish Orphan Biovitrium AB (publ) | S.O. | 2022-12-08 | 2028-12-08 | S.O | 2030-12-08 |
| pegvaliase | 251687 | Palynziq | BioMarin International Limited | S.O. | 2022-03-30 | 2028-03-30 | Oui | 2030-09-30 |
| pemigatinib | 242569 | Pemazyre | Incyte Corporation | S.O. | 2021-09-17 | 2027-09-17 | S.O. | 2029-09-17 |
| péramivir | 191280 | Rapivab | BioCryst Pharmaceuticals Inc. | S.O. | 2017-01-05 | 2023-01-05 | S.O. | 2025-01-05 |
| phénylbutyrate de glycérol | 174219 | Ravicti | Horizon Pharma Ireland Ltd. | S.O. | 2016-03-18 | 2022-03-18 | Oui | 2024-09-18 |
| plécanatide | 215288 | Trulance | Bausch Health, Canada Inc. | S.O. | 2019-10-10 | 2025-10-10 | S.O. | 2027-10-10 |
| polatuzumab vedotin | 232303 | Polivy | Hoffmann-La Roche Limited | S.O. | 2020-07-09 | 2026-07-09 | S.O | 2028-07-09 |
| polysaccharide pneumococcique sérotypes 22F et 33F conjugués à CRM-197 | 247042 | Vaxneuvance | Merk Canada Inc. | S.O. | 2021-11-16 | 2027-11-16 | Oui | 2030-05-16 |
| polysaccharide pneumococcique sérotypes 8, 10A, 11A, 12F et 15B conjugués individuellement à la protéine CRM197 | 253111 | Prevnar 20 | Pfizer Canada ULC | S.O. | 2022-05-09 | 2028-05-09 | Oui | 2030-11-09 |
| ponésimod | 239537 | Ponvory | Janssen Inc. | S.O. | 2021-04-28 | 2027-04-28 | S.O. | 2029-04-28 |
| pralatrexate | 207545 | Folotyn | Servier Canada Inc. | S.O. | 2018-10-26 | 2024-10-26 | S.O. | 2026-10-26 |
| pralsétinib | 243731 | Gavreto | Hoffmann-La Roche Limited | S.O. | 2021-06-30 | 2027-06-30 | S.O. | 2029-06-30 |
| prastérone | 198822 | Intrarosa | Cosette Pharmaceuticals, Inc. | S.O. | 2019-11-01 | 2025-11-01 | S.O. | 2027-11-01 |
| protéine de spicule du sras-cov-2 recombinante | 255370 | Nuvaxovid | Novavax Inc. | S.O. | 2022-02-17 | 2028-02-17 | Oui | 2030-08-17 |
| protéine de spicule du sras-cov-2 recombinante (omicron XBB.1.5) | 278519 | Nuvaxovid XBB.1.5 | Novavax Inc. | S.O. | 2023-12-05 | 2029-12-05 | S.O. | 2031-12-05 |
| protéine F de préfusion du virus respiratoire syncytial (RSVPreF3) | 269021 | Arexvy | GlaxoSmithKline Inc. | S.O. | 2023-08-04 | 2029-08-04 | S.O. | 2031-08-04 |
| protéine F stabilisée en conformation préfusion du VRS sous-groupe A et protéine F stabilisée en conformation préfusion du VRS sous-groupe B | 272785 | Abrysvo | Pfizer Canada ULC | S.O. | 2023-12-21 | 2029-12-21 | Oui | 2032-06-21 |
| pyrophosphate citrate ferrique | 239850 | Triferic Avnu | Rockwell Medical Inc. | S.O. | 2021-04-22 | 2027-04-22 | Oui | 2029-10-22 |
| ravulizumab | 217955 | Ultomiris | Alexion Pharma GmbH | S.O. | 2019-08-28 | 2025-08-28 | Oui | 2028-02-28 |
| raxtozinaméran | 276302 | Comirnaty Omicron XBB.1.5 | Comirnaty Omicron XBB.1.5 | S.O. | 2023-09-28 | 2029-09-28 | S.O | 2031-09-28 |
| relatlimab | 256629 | Opdualag | Bristol-Myers Squibb Canada | S.O. | 2023-09-13 | 2029-09-13 | Oui | 2032-03-13 |
| relugolix | 267148 | Myfembree | Sumitomo Pharma Switzerland GmbH | Orgovyx | 2023-09-22 | 2029-09-22 | S.O. | 2031-09-22 |
| remdésivir | 240551 | Veklury | Gilead Sciences Canada, Inc. | S.O. | 2020-07-27 | 2026-07-27 | Oui | 2029-01-27 |
| reslizumab | 185873 | Cinqair | Teva Canada Limited | S.O. | 2016-07-20 | 2022-07-20 | Oui | 2025-01-20 |
| ribociclib (sous forme de succinate de ribociclib) | 203884 | Kisqali | Novartis Pharmaceuticals Canada Inc. | S.O. | 2018-03-02 | 2024-03-02 | S.O. | 2026-03-02 |
| riltozinaméran | 266189 | Comirnaty Original / Omicron BA.1 | BioNTech Manufacturing GmbH | S.O. | 2022-10-21 | 2028-10-21 | Oui | 2031-04-21 |
| rimégépant | 268384 | Nurtec ODT | Pfizer Canada ULC | S.O. | 2023-12-01 | 2029-12-01 | S.O. | 2031-12-01 |
| riprétinib | 234688 | Qinlock | Deciphera Pharmaceuticals, LLC | S.O. | 2020-06-19 | 2026-06-19 | S.O | 2028-06-19 |
| risankizumab | 215753 | Skyrizi | AbbVie Corporation | S.O. | 2019-04-17 | 2025-04-17 | Oui | 2027-10-17 |
| risdiplam | 242373 | Evrysdi | Hoffman-La Roche Limited | S.O. | 2021-04-14 | 2027-04-14 | Oui | 2029-10-14 |
| romosozumab | 197713 | Evenity | Amgen Canada Inc. | S.O. | 2019-06-17 | 2025-06-17 | S.O. | 2027-06-17 |
| rupatadine (sous forme de fumarate de rupatadine) | 186488 | Rupall | Medexus Inc. | S.O. | 2016-07-20 | 2022-07-20 | Oui | 2025-01-20 |
| sacituzumab govitecan | 248753 | Trodelvy | Gilead Sciences Canada, Inc. | S.O. | 2021-09-24 | 2027-09-24 | S.O. | 2029-09-24 |
| sacubitril | 182734 | Entresto | Novartis Pharmaceuticals Canada Inc. | S.O. | 2015-10-02 | 2021-10-02 | Oui | 2024-04-02 |
| safinamide (safinamide mésylate) | 207115 | Onstryv | Valeo Pharma Inc. | S.O. | 2019-01-10 | 2025-01-10 | S.O. | 2027-01-10 |
| sarilumab | 191745 | Kevzara | Sanofi-Aventis Canada Inc. | S.O. | 2017-01-12 | 2023-01-12 | S.O. | 2025-01-12 |
| satralizumab | 233642 | Enspryng | Hoffmann-La Roche Limited | S.O. | 2020-06-01 | 2026-06-01 | Oui | 2028-12-01 |
| sébélipase alfa | 204085 | Kanuma | Alexion Pharma GmbH | S.O. | 2017-12-15 | 2023-12-15 | Oui | 2026-06-15 |
| selexipag | 182114 | Uptravi | Janssen Inc. | S.O. | 2016-01-20 | 2022-01-20 | Oui | 2024-07-20 |
| sélinexor | 253182 | Xpovio | FORUS Therapeutics Inc. | S.O. | 2022-05-31 | 2028-05-31 | S.O. | 2030-05-31 |
| selpercatinib | 243748 | Retevmo | Loxo Oncology Inc. | S.O. | 2021-06-15 | 2027-06-15 | Oui | 2029-12-15 |
| sémaglutide | 202059 | Ozempic | Novo Nordisk Canada Inc. | Rybelsus Wegovy |
2018-01-04 | 2024-01-04 | S.O. | 2026-01-04 |
| siponimod | 223225 | Mayzent | Novartis Pharmaceuticals Canada Inc. | S.O. | 2020-02-20 | 2026-02-20 | S.O. | 2028-02-20 |
| sodium de inotersen | 214274 | Tegsedi | Akcea Therapeutics Inc. | S.O. | 2018-10-03 | 2024-10-03 | S.O | 2026-10-03 |
| somapacitan | 267443 | Sogroya | Novo Nordisk Canada Inc. | S.O. | 2023-07-26 | 2029-07-26 | Oui | 2032-01-26 |
| somatrogon | 246729 | Ngenla | Pfizer Canada ULC | S.O. | 2021-10-26 | 2027-10-26 | Oui | 2030-04-26 |
| sonidegib phosphate | 229407 | Odomzo | Sun Pharmaceutical Industries Ltd. | S.O. | 2020-06-12 | 2026-06-12 | S.O. | 2028-06-12 |
| sotorasib | 248435 | Lumakras | Amgen Canada Inc. | S.O. | 2021-09-10 | 2027-09-10 | S.O | 2029-09-10 |
| spésolimab | 267362 | Spevigo | Boehringer Ingelheim (Canada) Ltd. | S.O. | 2023-03-22 | 2029-03-22 | S.O. | 2031-03-22 |
| sugammadex sodique | 180385 | Bridion | Merck Canada Inc. | S.O. | 2016-02-05 | 2022-02-05 | Oui | 2024-08-05 |
| sulfate de sélumétinib | 243733 | Koselugo | Alexion Pharma GmbH | S.O. | 2022-08-31 | 2028-08-31 | Oui | 2031-03-03 |
| sulfate de vorapaxar | 179320 | Zontivity | Xspire Pharma, LLC | S.O. | 2016-05-13 | 2022-05-13 | S.O. | 2024-05-13 |
| suvorexant | 196367 | Belsomra | Merck Canada Inc. | S.O. | 2018-11-29 | 2024-11-29 | S.O. | 2026-11-29 |
| tafamidis meglumine | 228368 | Vyndaqel | Pfizer Canada ULC | Vyndamax | 2020-01-20 | 2026-01-20 | S.O. | 2028-01-20 |
| tafasitamab | 247025 | Minjuvi | Incyte Corporation | S.O. | 2021-08-19 | 2027-08-19 | S.O. | 2029-08-19 |
| talazoparib (fourni comme talazoparib tosylate) | 220584 | Talzenna | Pfizer Canada ULC | S.O. | 2019-09-06 | 2025-09-06 | S.O. | 2027-09-06 |
| tartrate déliglustat | 183050 | Cerdelga | Sanofi Genzyme, A division of Sanofi-Aventis Canada Inc. | S.O. | 2017-04-21 | 2023-04-21 | S.O. | 2025-04-21 |
| tebentafusp | 258717 | Kimmtrak | Immunocore Ireland Limited | S.O. | 2022-06-07 | 2028-06-07 | S.O. | 2030-06-07 |
| teclistamab | 269369 | Tecvayli | Janssen Inc. | S.O. | 2023-07-26 | 2029-07-26 | S.O | 2031-07-26 |
| telotristat éthyl (comme telotristat etiprate) | 208730 | Xermelo | SERB SAS | S.O. | 2018-10-10 | 2024-10-10 | S.O. | 2026-10-10 |
| ténofovir alafenamide hemifumarate | 181399 | Genvoya | Gilead Sciences Canada Inc. | Descovy Odefsey Vemlidy Symtuza Biktarvy |
2015-11-27 | 2021-11-27 | Oui | 2024-05-27 |
| tepotinib (sous forme de chlorhydrate de tepotinib) | 242300 | Tepmetko | EMD Serono, a Division of EMD Inc., Canada | S.O. | 2021-05-27 | 2027-05-27 | S.O. | 2029-05-27 |
| tézacaftor | 211292 | Symdeko | Vertex Pharmaceuticals (Canada) Incorporated | Trikafta | 2018-06-27 | 2024-06-27 | Oui | 2026-12-27 |
| tézépelumab | 256188 | Tezspire | AstraZeneca Canada Inc. | S.O. | 2022-07-28 | 2028-07-28 | Oui | 2031-01-28 |
| tildrakizumab | 224036 | Ilumya | Sun Pharmaceutical Industries Ltd. | S.O. | 2021-05-19 | 2027-05-19 | S.O. | 2029-05-19 |
| tirbanibuline | 262080 | Onakta | AVIR Pharma Inc. | S.O. | 2023-05-12 | 2029-05-12 | S.O. | 2031-05-12 |
| tirzepatide | 259103 | Mounjaro | Eli Lilly Canada Inc. | S.O. | 2022-11-24 | 2028-11-24 | S.O. | 2030-11-24 |
| tisagenlecleucel | 213547 / 213698 | Kymriah | Novartis Pharmaceuticals Canada Inc. | S.O. | 2018-09-05 | 2024-09-05 | Oui | 2027-03-05 |
| tixagevimab / cilgavimab | 258295 | Evusheld | AstraZeneca Canada Inc. | S.O. | 2022-04-14 | 2028-04-14 | S.O. | 2030-04-14 |
| tosylate de ritlecitinib | 268723 | Litfulo | Pfizer Canada ULC | S.O. | 2023-11-29 | 2029-11-29 | Oui | 2032-05-29 |
| tozinaméran | 252736 | Comirnaty | BioNTech Manufacturing GmbH | Comirnaty Original & Omicron BA.4/BA.5 Comirnaty Original/Omicron BA.1 |
2021-09-16 | 2027-09-16 | Oui | 2030-03-16 |
| tralokinumab | 245877 | Adtralza | LEO Pharma Inc. | S.O. | 2021-10-13 | 2027-10-13 | Oui | 2030-04-13 |
| trastuzumab déruxtécan | 242104 | Enhertu | AstraZeneca Canada Inc. | S.O. | 2021-04-15 | 2027-04-15 | S.O. | 2029-04-15 |
| trémélimumab | 262740 | Imjudo | AstraZeneca Canada Inc. | S.O. | 2023-08-31 | 2029-08-31 | S.O. | 2031-08-31 |
| trifarotene | 221945 | Aklief | Galderma Canada Inc. | S.O. | 2019-11-25 | 2025-11-25 | Oui | 2028-05-25 |
| triheptanoin | 242196 | Dojolvi | Ultragenyx Pharmaceutical Inc. | S.O. | 2021-02-15 | 2027-02-15 | Oui | 2029-08-15 |
| tucatinib | 235295 | Tukysa | Seagen Inc. | S.O. | 2020-06-05 | 2026-06-05 | S.O. | 2028-06-05 |
| ubrogépant | 256191 | Ubrelvy | AbbVie Corporation | S.O. | 2022-11-10 | 2028-11-10 | S.O. | 2030-11-10 |
| upadacitinib | 223734 | Rinvoq | AbbVie Corporation | S.O. | 2019-12-23 | 2025-12-23 | Oui | 2028-06-23 |
| ursodoxicoltaurine | 253502 | Albrioza | Amylyx Pharmaceuticals Inc. | S.O. | 2022-06-10 | 2028-06-10 | S.O. | 2030-06-10 |
| vaccin ebola zaïre (rVSVΔG-ZEBOV-GP, vivant) | 256568 | Ervebo | Merck Canada Inc. | S.O. | 2022-11-09 | 2028-11-09 | S.O. | 2030-11-09 |
| velpatasvir | 190521 | Epclusa | Gilead Sciences Canada Inc. | Vosevi | 2016-07-11 | 2022-07-11 | Oui | 2025-01-11 |
| vénétoclax | 190761 | Venclexta | AbbVie Corporation | S.O. | 2016-09-30 | 2022-09-30 | S.O. | 2024-09-30 |
| vériciguat | 240862 | Verquvo | Bayer Inc. | S.O. | 2023-04-28 | 2029-04-28 | S.O. | 2031-04-28 |
| vorétigéne néparvovec | 233097 | Luxturna | Novartis Pharmaceuticals Canada Inc. | S.O. | 2020-10-13 | 2026-10-13 | Oui | 2029-04-13 |
| voxilaprévir | 202324 | Vosevi | Gilead Sciences Canada Inc. | S.O. | 2017-08-16 | 2023-08-16 | S.O. | 2025-08-16 |
| vutrisiran sodium | 267923 | Amvuttra | Alnylam Netherlands B.V. | S.O. | 2023-10-18 | 2029-10-18 | S.O. | 2031-10-18 |
| zanubrutinib | 242748 | Brukinsa | BeiGene Switzerland GmbH | S.O. | 2021-03-01 | 2027-03-01 | S.O. | 2029-03-01 |
| Ingrédient(s) médicinal(aux) Footnote 1 |
Nº de la présentation | Drogue innovante | Nom du fabricant | Drogue(s) contenant l'ingrédient médicinal / variante | Date de l'avis de conformité aaaa-mm-jj |
Date de la période de "non-dépôt" de 6 ans | Prolongation pédiatrique Oui ou Non |
Fin de la période de protection des données |
|---|---|---|---|---|---|---|---|---|
| empagliflozine | 162552 | Jardiance | Boehringer Ingelheim (Canada) Ltd. | Synjardy Glyxambi |
2015-07-23 | 2021-07-23 | S.O. | 2023-07-23 |
| vedolizumab | 169414 | Entyvio | Takeda Canada Inc. | S.O. | 2015-01-29 | 2021-01-29 | Oui | 2023-07-29 |
| abatacept | 098531 | Orencia | Bristol-Myers Squibb Canada | S.O. | 2006-06-29 | 2012-06-29 | Oui | 2014-12-29 |
| acamprosate calcique | 103287 | Campral | Mylan Pharmaceuticals ULC | S.O. | 2007-03-16 | 2013-03-16 | S.O. | 2015-03-16 |
| acétate d'icatibant | 162918 | Firazyr | Takeda Canada Inc. | S.O. | 2014-06-04 | 2020-06-04 | Oui | 2022-12-04 |
| acétate d'abiratérone | 138343 | Zytiga | Janssen Inc. | S.O. | 2011-07-27 | 2017-07-27 | S.O. | 2019-07-27 |
| acétate de bazédoxifene | 160681 | Duavive | Pfizer Canada Inc. | S.O. | 2014-10-23 | 2020-10-23 | S.O. | 2022-10-23 |
| acétate de dégarélix | 120421 | Firmagon | Ferring Inc. | S.O. | 2009-11-16 | 2015-11-16 | S.O. | 2017-11-16 |
| acétate d'eslicarbazépine | 165665 | Aptiom | Sunovion Pharmaceuticals Canada Inc. | S.O. | 2014-07-08 | 2020-07-08 | Oui | 2023-01-08 |
| acétate d'ulipristal | 156861 | Fibristal | Allergan Inc. | S.O. | 2013-06-24 | 2019-06-24 | S.O. | 2021-06-24 |
| acide carglumique | 171358 | Carbaglu | Recordati Rare Diseases | S.O. | 2015-04-10 | 2021-04-10 | Oui | 2023-10-10 |
| aflibercept | 149321 | Eylea | Bayer Inc. | S.O. | 2013-11-08 | 2019-11-08 | S.O. | 2021-11-08 |
| albiglutide | 165145 | Eperzan | GlaxoSmithKline Inc. | S.O. | 2015-07-15 | 2021-07-15 | S.O. | 2023-07-15 |
| alglucosidase alfa | 103381 | Myozyme | Genzyme Canada Inc. | S.O. | 2006-08-14 | 2012-08-14 | Oui | 2015-02-14 |
| ambrisentan | 113287 | Volibris | GlaxoSmithKline Inc. | S.O. | 2008-03-20 | 2014-03-20 | S.O. | 2016-03-20 |
| anidulafungine | 110202 | Eraxis | Pfizer Canada Inc. | S.O. | 2007-11-14 | 2013-11-14 | Oui | 2016-05-14 |
| apixaban | 141873 | Eliquis | Bristol-Myers Squibb Canada | S.O. | 2011-12-16 | 2017-12-16 | Oui | 2020-06-16 |
| aprémilast | 169862 | Otezla | Amgen Canada Inc. | S.O. | 2014-11-12 | 2020-11-12 | S.O. | 2022-11-12 |
| aprépitant | 108483 | Emend | Merck Frosst Canada Ltd. | Emend Tri-Pack Emend IV |
2007-08-24 | 2013-08-24 | S.O. | 2015-08-24 |
| aripiprazole | 120192 | Abilify | Bristol-Myers Squibb Canada | Abilify Maintena | 2009-07-09 | 2015-07-09 | Oui | 2018-01-09 |
| asfotase alfa | 179340 | Strensiq | Alexion Pharma International Sàrl | S.O. | 2015-08-14 | 2021-08-14 | Oui | 2024-02-14 |
| asunaprévir | 172617 | Sunvepra | Bristol-Myers Squibb Canada | S.O. | 2016-03-09 | 2022-03-09 | S.O. | 2024-03-09 |
| axitinib | 144404 | Inlyta | Pfizer Canada Inc. | S.O. | 2012-07-12 | 2018-07-12 | Oui | 2021-01-12 |
| azacitidine | 127108 | Vidaza | Celgene | S.O. | 2009-10-23 | 2015-10-23 | S.O. | 2017-10-23 |
| azilsartan médoxomil potassium | 145305 | Edarbi | Valeant Canada LP | Edarbyclor | 2012-03-08 | 2018-03-08 | S.O. | 2020-03-08 |
| bélimumab | 137699 | Benlysta | GlaxoSmithKline Inc. | S.O. | 2011-07-06 | 2017-07-06 | S.O. | 2019-07-06 |
| benzoate d'alogliptine | 158335 | Nesina | Takeda Canada Inc. | Kazano Oseni |
2013-11-27 | 2019-11-27 | S.O. | 2021-11-27 |
| bésifloxacin | 123400 | Besivance | Bausch & Lomb Inc. | S.O. | 2009-10-23 | 2015-10-23 | Oui | 2018-04-23 |
| bocèprèvir | 141556 | Victrelis | Merck Canada Inc. | Victrelis Triple | 2011-07-29 | 2017-07-29 | S.O. | 2019-07-29 |
| bosutinib | 152211 | Bosulif | Pfizer Canada Inc. | S.O. | 2014-03-07 | 2020-03-07 | S.O. | 2022-03-07 |
| brentuximab védotine | 154851 | Adcetris | Seattle Genetics Inc. | S.O. | 2013-02-01 | 2019-02-01 | S.O. | 2021-02-01 |
| bromfénac sodique sesquihydraté | 171657 | Prolensa | Bausch & Lomb Incorporated | S.O. | 2015-03-26 | 2021-03-26 | S.O. | 2023-03-26 |
| bromhydrate de vortioxétine | 159019 | Trintellix | Lundbeck Canada Inc. | S.O. | 2014-10-22 | 2020-10-22 | Oui | 2023-04-22 |
| bromure d'aclidinium | 157598 | Tudorza Genuair | AstraZeneca Canada Inc. | Duaklir Genuair | 2013-07-29 | 2019-07-29 | S.O. | 2021-07-29 |
| bromure de méthylnal | 114266 | Relistor | Salix Pharmaceuticals, Inc. | S.O. | 2008-03-28 | 2014-03-28 | S.O. | 2016-03-28 |
| bromure d'uméclidinium | 161585 | Anoro Ellipta | GlaxoSmithKline Inc. | Incruse Ellipta | 2013-12-23 | 2019-12-23 | S.O. | 2021-12-23 |
| cabazitaxel | 137421 | Jevtana | Sanofi-aventis Canada Inc. | S.O. | 2011-06-16 | 2017-06-16 | Oui | 2019-12-16 |
| canagliflozine | 157505 | Invokana | Janssen Inc. | Invokamet Invokamet XR |
2014-05-23 | 2020-05-23 | S.O. | 2022-05-23 |
| canakinumab | 131009 | Ilaris | Novartis Pharmaceuticals Canada Inc. | S.O. | 2010-02-26 | 2016-02-26 | Oui | 2018-08-26 |
| carbonate hydrate de lanthane | 102240 | Fosrenol | Shire BioChem Inc. | S.O. | 2006-10-17 | 2012-10-17 | S.O. | 2014-10-17 |
| carfilzomib | 184479 | Kyprolis | Amgen Canada Inc. | S.O. | 2016-01-15 | 2022-01-15 | S.O. | 2024-01-15 |
| catridécacog | 152228 | Tretten | Novo Nordisk Canada Inc. | S.O. | 2012-07-19 | 2018-07-19 | Oui | 2021-01-19 |
| catumaxomab | 142629 | Removab | Fresenius Biotech GmbH | S.O. | 2012-05-11 | 2018-05-11 | S.O. | 2020-05-11 |
| ceftobiprole médocaril | 112752 | Zeftera | Janssen Inc. | S.O. | 2008-06-26 | 2014-06-26 | S.O. | 2016-06-26 |
| ceftolozane | 178006 | Zerbaxa | Merck Canada Inc. | S.O. | 2015-09-30 | 2021-09-30 | S.O. | 2023-09-30 |
| ceritinib | 175702 | Zykadia | Novartis Pharmaceuticals Canada Inc. | S.O. | 2015-03-27 | 2021-03-27 | S.O. | 2023-03-27 |
| certolizumab pégol | 120296 | Cimzia | UCB Canada Inc. | S.O. | 2009-08-12 | 2015-08-12 | S.O. | 2017-08-12 |
| chlohydrate de guanfacine | 150741 | Intuniv XR | Takeda Canada Inc. | S.O. | 2013-07-05 | 2019-07-05 | Oui | 2022-01-05 |
| chlohydrate de nébivolol | 152353 | Bystolic | Allergan Inc. | S.O. | 2012-12-21 | 2018-12-21 | S.O. | 2020-12-21 |
| chlorhydrate de bendamustine | 149814 | Treanda | Teva Canada Limited | S.O. | 2012-08-24 | 2018-08-24 | Oui | 2021-02-24 |
| chlorhydrate de colésévélam | 133463 | Lodalis | Valeant Canada LP / Valeant Canada S.E.C. | S.O. | 2011-09-22 | 2017-09-22 | S.O. | 2019-09-22 |
| chlorhydrate de dexmédétomidine | 126931 | Precedex | Pfizer Canada Inc. | S.O. | 2009-12-09 | 2015-12-09 | Oui | 2018-06-09 |
| chlorhydrate de dronédarone | 121065 | Multaq | Sanofi-aventis Canada Inc. | S.O. | 2009-08-11 | 2015-08-11 | S.O. | 2017-08-11 |
| chlorhydrate de duloxétine | 110028 | Cymbalta | Eli Lilly Canada Inc. | S.O. | 2007-11-01 | 2013-11-01 | Oui | 2016-05-01 |
| chlorhydrate de fingolimod | 137516 | Gilenya | Novartis Pharmaceuticals Canada Inc. | S.O. | 2011-03-09 | 2017-03-09 | S.O. | 2019-03-09 |
| chlorhydrate de lévomilnacipran | 167319 | Fetzima | Abbvie Corporation | S.O. | 2015-05-08 | 2021-05-08 | S.O. | 2023-05-08 |
| chlorhydrate de lurasidone | 145406 | Latuda | Sunovion Pharmaceuticals Canada Inc. | S.O. | 2012-06-13 | 2018-06-13 | Oui | 2020-12-13 |
| chlorhydrate de nilotinib monohydraté | 110305 | Tasigna | Novartis Pharmaceuticals Canada Inc. | S.O. | 2008-09-09 | 2014-09-09 | S.O. | 2016-09-09 |
| chlorhydrate de palonosétron | 145491 | Aloxi | Purdue Pharma | Akynzeo | 2012-03-14 | 2018-03-14 | S.O. | 2020-03-14 |
| chlorhydrate de pazopanib | 128332 | Votrient | Novartis Pharmaceuticals Canada Inc. | S.O. | 2010-05-27 | 2016-05-27 | S.O. | 2018-05-27 |
| chlorhydrate de pembrolizumab | 175884 | Keytruda | Merck Canada Inc. | S.O. | 2015-05-19 | 2021-05-19 | Oui | 2023-11-19 |
| chlorhydrate de ponatinib | 165121 | Iclusig | Ariad Pharmaceuticals Inc. | S.O. | 2015-04-02 | 2021-04-02 | S.O. | 2023-04-02 |
| chlorhydrate de prasugrel | 121143 | Effient | Eli Lilly Canada Inc. | S.O. | 2010-04-16 | 2016-04-16 | Oui | 2018-10-16 |
| chlorhydrate de rilpivirine | 137484 | Edurant | Janssen Inc. | Complera Odefsey Juluca |
2011-07-21 | 2017-07-21 | Oui | 2020-01-21 |
| chlorhydrate de saxagliptine | 123854 | Onglyza | AstraZeneca Canada Inc. | Komboglyze Qtern |
2009-09-14 | 2015-09-14 | S.O. | 2017-09-14 |
| chlorhydrate de tapentadol | 133167 | Nucynta CR | Janssen Inc. | Nucynta IR Nucynta Extended Release |
2010-12-02 | 2016-12-02 | S.O. | 2018-12-02 |
| chlorhydrate de télavancine | 107792 | Vibativ | Pendopharm Division of de Pharmascience Inc. | S.O. | 2009-09-29 | 2015-09-29 | S.O. | 2017-09-29 |
| chlorhydrate de ziprasidone monohydrate | 078188 | Zeldox | Pfizer Canada Inc. | S.O. | 2007-08-27 | 2013-08-27 | Oui | 2016-02-27 |
| chlorhydrate d'olodatérol | 155649 | Striverdi Respimat | Boehringer Ingelheim (Canada) Ltd. | Inspiolto Respimat | 2013-06-11 | 2019-06-11 | S.O. | 2021-06-11 |
| chlorure de radium 223 | 161312 | Xofigo | Bayer Inc. | S.O. | 2013-12-12 | 2019-12-12 | S.O. | 2021-12-12 |
| chlorure de rubidium 82 | 138823 | Ruby-Fill | Jubilant Draximage Inc. | S.O. | 2011-09-20 | 2017-09-20 | S.O. | 2019-09-20 |
| ciclésonide | 101419 | Alvesco | Takeda Canada Inc. | Omnaris Omnaris HFA |
2006-09-11 | 2012-09-11 | Oui | 2015-03-11 |
| clévidipine | 125287 | Cleviprex | Chiesi Farmaceutici S.p.A. | S.O. | 2011-04-15 | 2017-04-15 | S.O. | 2019-04-15 |
| clofarabine | 121874 | Clolar | Sanofi-aventis Canada Inc. | S.O. | 2009-07-16 | 2015-07-16 | Oui | 2018-01-16 |
| cobimétinib | 182788 | Cotellic | Hoffmann-La Roche Limited | S.O. | 2016-02-22 | 2022-02-22 | S.O. | 2024-02-22 |
| collagénase de clostridium histolyticum | 147788 | Xiaflex | Endo Ventures Ltd. | S.O. | 2012-07-05 | 2018-07-05 | S.O. | 2020-07-05 |
| crizotinib | 145155 | Xalkori | Pfizer Canada Inc. | S.O. | 2012-04-25 | 2018-04-25 | Oui | 2020-10-25 |
| dabigatran étexilate mésilate | 114887 | Pradaxa | Boehringer Ingelheim (Canada) Ltd. | S.O. | 2008-06-10 | 2014-06-10 | S.O. | 2016-06-10 |
| daclatasvir | 172616 | Daklinza | Bristol-Myers Squibb Canada | S.O. | 2015-08-13 | 2021-08-13 | S.O. | 2023-08-13 |
| dapagliflozin propanediol | 160877 | Forxiga | AstraZeneca Canada Inc. | Xigduo Qtern |
2014-12-12 | 2020-12-12 | S.O. | 2022-12-12 |
| daptomycine | 102320 | Cubicin | Cubist Pharmaceuticals, Incorporated | S.O. | 2007-09-24 | 2013-09-24 | Oui | 2016-03-24 |
| déférasirox | 099621 | Exjade | Novartis Pharmaceuticals Canada Inc. | S.O. | 2006-10-18 | 2012-10-18 | Oui | 2015-04-18 |
| défériprone | 162924 | Ferriprox | Chiesi Canada Corp. | S.O. | 2015-02-13 | 2021-02-13 | Oui | 2023-08-13 |
| dénosumab | 121139 | Prolia | Amgen Canada Inc. | Xgeva | 2010-08-06 | 2016-08-06 | S.O. | 2018-08-06 |
| dichlorhydrate de saproptérine | 128151 | Kuvan | BioMarin Pharmaceutical Inc. | S.O. | 2010-04-30 | 2016-04-30 | Oui | 2018-10-30 |
| dienogest | 132174 | Visanne | Bayer Inc. | Natazia | 2011-10-12 | 2017-10-12 | Oui | 2020-04-12 |
| difluprednate | 154517 | Durezol | Novartis Pharmaceuticals Canada Inc. | S.O. | 2013-11-04 | 2019-11-04 | Oui | 2022-05-04 |
| dimaléate d'afatinib | 158730 | Giotrif | Boehringer Ingelheim (Canada) Ltée | S.O. | 2013-11-01 | 2019-11-01 | S.O. | 2021-11-01 |
| dimesylate de lisdexamfetamine | 120534 | Vyvanse | Shire Pharma Canada ULC. | S.O. | 2009-02-19 | 2015-02-19 | Oui | 2017-08-19 |
| dimethyl fumarate | 154776 | Tecfidera | Biogen Idec Canada Inc. | S.O. | 2013-04-03 | 2019-04-03 | Oui | 2021-10-03 |
| ditosylate de lapatinib | 110294 | Tykerb | Novartis Pharmaceuticals Canada Inc. | S.O. | 2009-05-15 | 2015-05-15 | S.O. | 2017-05-15 |
| dolutégravir de sodium | 161084 | Tivicay | ViiV Healthcare ULC | Triumeq Juluca Dovato |
2013-10-31 | 2019-10-31 | Oui | 2022-05-01 |
| doripenem monohydrate | 113640 | Doribax | Janssen Inc. | S.O. | 2009-09-02 | 2015-09-02 | S.O. | 2017-09-02 |
| dulaglutide | 168671 | Trulicity | Eli Lilly Canada Inc. | S.O. | 2015-11-10 | 2021-11-10 | S.O. | 2023-11-10 |
| éculizumab | 122467 | Soliris | Alexion Pharma International Sàrl | S.O. | 2009-01-28 | 2015-01-28 | Oui | 2017-07-28 |
| éfinaconazole | 159416 | Jublia | Bausch Health, Canada Inc. | S.O. | 2013-10-02 | 2019-10-02 | S.O. | 2021-10-02 |
| élosulfase alfa | 170340 | Vimizim | Biomarin International Limited | S.O. | 2014-07-02 | 2020-07-02 | Oui | 2023-01-02 |
| elvitégravir, cobicistat | 152198 | Stribild | Gilead Sciences Canada Inc. | Tybost Vitekta Prezcobix Evotaz Genvoya Symtuza |
2012-11-26 | 2018-11-26 | S.O. | 2020-11-26 |
| emtansine de trastuzumab | 162414 | Kadcyla | Hoffmann-La Roche Limited | S.O. | 2013-09-11 | 2019-09-11 | S.O. | 2021-09-11 |
| enzalutamide | 159678 | Xtandi | Astellas Pharma Canada Inc. | S.O. | 2013-05-29 | 2019-05-29 | S.O. | 2021-05-29 |
| éplérénone | 120440 | Inspra | Pfizer Canada Inc. | S.O. | 2009-02-26 | 2015-02-26 | Oui | 2017-08-26 |
| éribuline mésylate | 141946 | Halaven | Eisai Limited | S.O. | 2011-12-14 | 2017-12-14 | S.O. | 2019-12-14 |
| étabonate de lotéprednol | 117199 | Alrex | Bausch & Lomb Inc. | Lotemax Lotemax Ointment Lotemax Gel |
2008-12-23 | 2014-12-23 | S.O. | 2016-12-23 |
| éthanolate de darunavir | 103324 | Prezista | Janssen Inc. | S.O. | 2006-07-28 | 2012-07-28 | Oui | 2015-01-28 |
| étravirine | 113100 | Intelence | Janssen Inc. | S.O. | 2008-03-27 | 2014-03-27 | Oui | 2016-09-27 |
| évérolimus | 125809 | Afinitor | Novartis Pharmaceuticals Canada Inc. | Certican | 2009-12-14 | 2015-12-14 | Oui | 2018-06-14 |
| évolocumab | 178234 | Repatha | Amgen Canada Inc. | S.O. | 2015-09-10 | 2021-09-10 | Oui | 2024-03-10 |
| exenatide | 128932 | Byetta | AstraZenaca Canada Inc. | Bydureon | 2011-01-13 | 2017-01-13 | S.O. | 2019-01-13 |
| ezogabine | 134659 | Potiga | GlaxoSmithKline Inc. | S.O. | 2012-10-18 | 2018-10-18 | S.O. | 2020-10-18 |
| facteur antihémophilique (recombinant BDD), protéine de fusion FC | 163447 | Eloctate | Sanofi-Aventis Canada Inc. | S.O. | 2014-08-22 | 2020-08-22 | Oui | 2023-02-22 |
| facteur antihémophilique (recombinant, le domaine B) (également connu comme simoctocog alfa) | 169551 | Nuwiq | Octapharma Pharmazeutika Produktionsges m.b.H | S.O. | 2014-10-23 | 2020-10-23 | Oui | 2023-04-23 |
| facteur VIII porcin recombinant (facteur anthémophilique (recombinant), séquence porcine) | 177290 | Obizur | Takeda Canada Inc. | S.O. | 2015-10-14 | 2021-10-14 | S.O. | 2023-10-14 |
| fampridine | 132859 | Fampyra | Biogen Idec Canada Inc. | S.O. | 2012-02-10 | 2018-02-10 | S.O. | 2020-02-10 |
| fébuxostat | 129969 | Uloric | Takeda Canada Inc. | S.O. | 2010-09-22 | 2016-09-22 | S.O. | 2018-09-22 |
| férumoxytol | 133250 | Feraheme | AMAG Pharmaceuticals Inc. | S.O. | 2011-12-08 | 2017-12-08 | S.O. | 2019-12-08 |
| fidaxomicin | 151086 | Dificid | Merck Canada Inc. | S.O. | 2012-06-07 | 2018-06-07 | S.O. | 2020-06-07 |
| fludésoxyglucose 18F | 091404 | Cantrace | Ipet Pharmaceuticals Inc. | S.O. | 2006-07-27 | 2012-07-27 | S.O. | 2014-07-27 |
| fluoride de sodium 18F | 145561 | NaF Plus | Isologic Innovative Radiopharmaceuticals Ltd. | S.O. | 2013-02-11 | 2019-02-11 | S.O. | 2021-02-11 |
| fumarate de fésotérodine | 142326 | Toviaz | Pfizer Canada Inc. | S.O. | 2012-02-09 | 2018-02-09 | Oui | 2020-08-09 |
| furoate de fluticasone | 107372 | Avamys | GlaxoSmithKline Inc. | S.O. | 2007-08-14 | 2013-08-14 | Oui | 2016-02-14 |
| gadofosveset trisodique | 096420 | Vasovist | Berlex Canada Inc. | S.O. | 2006-10-31 | 2012-10-31 | S.O. | 2014-10-31 |
| gadoxétate disodique | 127609 | Primovist | Bayer Inc. | S.O. | 2010-01-14 | 2016-01-14 | S.O. | 2018-01-14 |
| galsulfase | 159020 | Naglazyme | BioMarin Pharmaceutical Inc. | S.O. | 2013-09-16 | 2019-09-16 | Oui | 2022-03-16 |
| golimumab | 120525 | Simponi | Janssen Inc. | S.O. | 2009-04-07 | 2015-04-07 | S.O. | 2017-04-07 |
| grazoprévir, elbasvir | 185866 | Zepatier | Merck Canada Inc. | S.O. | 2016-01-19 | 2022-01-19 | S.O. | 2024-01-19 |
| haemagglutinine-souche A (H5N1) | 115398 | Arepanrix H5N1 | ID Biomedical Corporation of Quebec | S.O. | 2013-02-13 | 2019-02-13 | Oui | 2021-08-13 |
| hémifumarate d'aliskirène | 105388 | Rasilez | Novartis Pharmaceuticals Canada Inc. | Rasilez HCT Rasilamlo |
2007-11-14 | 2013-11-14 | S.O. | 2015-11-14 |
| hydrochloride d' azélastine | 169604 | Dymista | BGP Pharma ULC | S.O. | 2014-10-23 | 2020-10-23 | Oui | 2023-04-23 |
| hydrochlorure de vilazodone | 176820 | Viibryd | AbbVie Corporation | S.O. | 2015-07-16 | 2021-07-16 | Oui | 2024-01-16 |
| ibrutinib | 174029 | Imbruvica | Janssen Inc. | S.O. | 2014-11-17 | 2020-11-17 | Oui | 2023-05-17 |
| idébénone | 117672 | Catena | Santhera Pharmaceuticals Ltd. | S.O. | 2008-07-23 | 2014-07-23 | Oui | 2017-01-23 |
| idelalisib | 172652 | Zydelig | Gilead Sciences Canada Inc. | S.O. | 2015-03-27 | 2021-03-27 | S.O. | 2023-03-27 |
| idursulfase | 109857 | Elaprase | Shire Human Genetic Therapies, Inc. | S.O. | 2007-06-13 | 2013-06-13 | Oui | 2015-12-13 |
| inhibiteur de la C1 estérase humaine | 121221 | Berinert | CSL Behring Canada Inc. | Haegarda | 2010-05-31 | 2016-05-31 | S.O. | 2018-05-31 |
| ipilimumab | 138178 | Yervoy | Bristol-Myers Squibb Canada | S.O. | 2012-02-01 | 2018-02-01 | Oui | 2020-08-01 |
| ivacaftor | 155318 | Kalydeco | Vertex Pharmaceuticals (Canada) Inc. | Orkambi Symdeko |
2012-11-26 | 2018-11-26 | Oui | 2021-05-26 |
| ivermectine | 172733 | Rosiver | Galderma Canada Inc. | S.O. | 2015-04-22 | 2021-04-22 | S.O | 2023-04-22 |
| lacosamide | 116632 | Vimpat | UCB Canada Inc. | S.O. | 2010-09-30 | 2016-09-30 | S.O. | 2018-09-30 |
| lanréotide | 098949 | Somatuline Autogel | Ipsen Biopharm Limited | S.O. | 2006-07-17 | 2012-07-17 | S.O. | 2014-07-17 |
| lédipasvir | 173180 | Harvoni | Gilead Sciences Canada Inc. | S.O. | 2014-10-15 | 2020-10-15 | Oui | 2023-04-15 |
| lénalidomide | 111952 | Revlimid | Celgene | S.O. | 2008-01-17 | 2014-01-17 | S.O. | 2016-01-17 |
| linaclotide | 161056 | Constella | Forest Laboratories Canada Inc. | S.O. | 2013-12-02 | 2019-12-02 | S.O. | 2021-12-02 |
| linagliptin | 140881 | Trajenta | Boehringer Ingelheim (Canada) Ltd. | Jentadueto Glyxambi |
2011-07-28 | 2017-07-28 | S.O. | 2019-07-28 |
| liraglutide | 119928 | Victoza | Novo Nordisk Canada Inc. | Saxenda Xultophy |
2010-05-21 | 2016-05-21 | S.O. | 2018-05-21 |
| lubiprostone | 179333 | Amitiza | Sucampo Pharma Americas LLC | S.O. | 2015-10-14 | 2021-10-14 | S.O. | 2023-10-14 |
| lumiracoxib | 102465 | Prexige | Novartis Pharmaceuticals Canada Inc. | S.O. | 2006-11-02 | 2012-11-02 | S.O. | 2014-11-02 |
| macitentan | 161372 | Opsumit | Janssen Inc. | Opsynvi | 2013-11-06 | 2019-11-06 | Oui | 2022-05-06 |
| maléate d'asénapine | 127427 | Saphris | Merck Canada Inc. | S.O. | 2011-10-07 | 2017-10-07 | Oui | 2020-04-07 |
| maléate d'indacatérol | 143984 | Onbrez Breezhaler | Novartis Pharmaceuticals Canada Inc. | Ultibro Breezhaler | 2011-12-06 | 2017-12-06 | S.O. | 2019-12-06 |
| maraviroc | 112435 | Celsentri | ViiV Healthcare ULC | S.O. | 2007-09-21 | 2013-09-21 | S.O. | 2015-09-21 |
| mébutate d'ingénol | 153285 | Picato | Leo Pharma Inc. | S.O. | 2013-01-30 | 2019-01-30 | S.O. | 2021-01-30 |
| mésylate de dabrafenib | 157590 | Tafinlar | Novartis Pharmaceuticals Canada Inc. | S.O. | 2013-07-16 | 2019-07-16 | S.O. | 2021-07-16 |
| mésylate de lomitapide | 160385 | Juxtapid | Aegerion Pharmaceuticals Canada Ltd. | S.O. | 2014-02-04 | 2020-02-04 | S.O. | 2022-02-04 |
| mésylate de rasagiline | 101846 | Azilect | Teva Pharmaceuticals Industries Ltd. | S.O. | 2006-08-17 | 2012-08-17 | S.O. | 2014-08-17 |
| méthoxy polyéthylene glycol-époétin beta | 106461 | Mircera | Hoffmann-La Roche Ltd. | S.O. | 2008-03-31 | 2014-03-31 | S.O. | 2016-03-31 |
| micafungin sodique | 078577 | Mycamine | Astellas Pharma Canada, Inc. | S.O. | 2007-05-22 | 2013-05-22 | S.O. | 2015-05-22 |
| mifépristone | 160063 | Mifegymiso | Linepharma International Limited | S.O. | 2015-07-29 | 2021-07-29 | Oui | 2024-01-29 |
| mirabégron | 153806 | Myrbetriq | Astellas Pharma Canada Inc. | S.O. | 2013-03-06 | 2019-03-06 | S.O. | 2021-03-06 |
| monohydrate de dasatinib | 104993 | Sprycel | Bristol-Myers Squibb Canada | S.O. | 2007-03-26 | 2013-03-26 | S.O. | 2015-03-26 |
| natalizumab | 093001 | Tysabri | Biogen Idec Canada Inc. | S.O. | 2006-09-28 | 2012-09-28 | S.O. | 2014-09-28 |
| nélarabine | 099994 | Atriance | Novartis Pharmaceuticals Canada Inc. | S.O. | 2007-09-22 | 2013-09-22 | Oui | 2016-03-22 |
| népafénac | 114004 | Nevanac | Alcon Canada Inc. | Ilevro | 2008-04-17 | 2014-04-17 | S.O. | 2016-04-17 |
| nesiritide | 111760 | Natrecor | Janssen Inc. | S.O. | 2007-11-08 | 2013-11-08 | S.O. | 2015-11-08 |
| nintédanib (fourni comme nintédanib esilate) | 176043 | Ofev | Boehringer Ingelheim (Canada) Ltd | S.O. | 2015-06-25 | 2021-06-25 | S.O. | 2023-06-25 |
| obinutuzumab | 168227 | Gazyva | Hoffmann-La Roche Limited | S.O. | 2014-11-25 | 2020-11-25 | S.O. | 2022-11-25 |
| ocriplasmine | 161356 | Jetrea | ThromboGenics N.V. | S.O. | 2013-08-13 | 2019-08-13 | S.O. | 2021-08-31 |
| ofatumumab | 128188 | Arzerra | Novartis Pharmaceuticals Canada Inc. | S.O. | 2012-03-09 | 2018-03-09 | S.O. | 2020-03-09 |
| olamine d'eltrombopag | 123984 | Revolade | Novartis Pharmaceuticals Canada Inc. | S.O. | 2011-01-12 | 2017-01-12 | Oui | 2019-07-12 |
| olmésartan médoxomil | 115991 | Olmetec | Merck Canada Inc. | Olmetec Plus | 2008-10-28 | 2014-10-28 | Oui | 2017-04-28 |
| ombitasvir, paritaprévir, dasabuvir sodium | 174739 | Holkira Pak | Abbvie Corporation | Technivie | 2014-12-22 | 2020-12-22 | S.O. | 2022-12-22 |
| oxalate de naloxegol | 167790 | Movantik | Knight Therapeutics Inc. | S.O. | 2015-06-02 | 2021-06-02 | S.O. | 2023-06-02 |
| oxaliplatine | 109965 | Eloxatin | Sanofi-aventis Canada Inc. | S.O. | 2007-06-15 | 2013-06-15 | Oui | 2015-12-15 |
| palipéridone | 108748 | Invega | Janssen Inc. | Invega Sustenna | 2007-09-26 | 2013-09-26 | Oui | 2016-03-26 |
| panitumumab | 105601 | Vectibix | Amgen Canada Inc. | S.O. | 2008-04-03 | 2014-04-03 | S.O. | 2016-04-03 |
| pasiréotide diaspartate | 145005 | Signifor | Novartis Pharmaceuticals Canada Inc. | Signifor Lar | 2013-09-23 | 2019-09-23 | S.O. | 2021-09-23 |
| peginterféron beta-1a | 166974 | Plegridy | Biogen Idec Canada Inc. | S.O. | 2015-08-10 | 2021-08-10 | S.O | 2023-08-10 |
| pérampanel | 153747 | Fycompa | Eisai Limited | S.O. | 2013-04-04 | 2019-04-04 | Oui | 2021-10-04 |
| pertuzumab | 158419 | Perjeta | Hoffmann-La Roche Limited | Perjeta-Herceptin Combo Pack Phesgo |
2013-04-12 | 2019-04-12 | S.O. | 2021-04-12 |
| phosphate de ruxolitinib | 151723 | Jakavi | Novartis Pharmaceuticals Canada Inc. | S.O. | 2012-06-19 | 2018-06-19 | S.O. | 2020-06-19 |
| phosphate de sitagliptine | 103039 | Januvia | Merck Frosst Canada Ltd. | Janumet Janumet XR |
2007-12-14 | 2013-12-14 | S.O. | 2015-12-14 |
| phosphate tedizolid | 173603 | Sivextro | Merck Canada Inc. | S.O. | 2015-03-17 | 2021-03-17 | S.O. | 2023-03-17 |
| pirfénidone | 153849 | Esbriet | Hoffmann-La Roche Limited | S.O. | 2012-10-01 | 2018-10-01 | S.O. | 2020-10-01 |
| plerixafor | 142638 | Mozobil | Sanofi-aventis Canada Inc. | S.O. | 2011-12-08 | 2017-12-08 | S.O. | 2019-12-08 |
| polidocanol | 177359 | Varithena | Provensis Ltd. | S.O. | 2015-08-04 | 2021-08-04 | S.O. | 2023-08-04 |
| polysaccharide de Neisseria meningitidis, sérogroupe A, Polysaccharide de Neisseria meningitidis, sérogroupe C, Polysaccharide de Neisseria meningitidis, sérogroupe W-135, Polysaccharide de Neisseria meningitidis, sérogroupe Y, conjugués à l'anatoxine tétanique comme vecteur protéique | 154290 | Nimenrix | Pfizer Canada Inc. | S.O. | 2013-03-05 | 2019-03-05 | Oui | 2021-09-05 |
| polysaccharide du pneumocoque de sérotype 1, 4, 5, 6B, 7F, 9V, 14, 23F conjugué à une protéine D comme porteur; sérotype 18C conjugué à l'anatoxine tétanique comme porteur; sérotype 19F conjugué à l'anatoxine diphtérique comme porteur | 119056 | Synflorix | GlaxoSmithKline Inc. | S.O. | 2008-12-11 | 2014-12-11 | Oui | 2017-06-11 |
| polysaccharide pneumococcique de sérotype 1, 3, 5, 6A, 7F, 19A conjugué à la protéine vectrice CRM197 | 122881 | Prevnar 13 | Pfizer Canada Inc. | S.O. | 2009-12-21 | 2015-12-21 | Oui | 2018-06-21 |
| pomalidomide | 165891 | Pomalyst | Celgene Inc. | S.O. | 2014-01-20 | 2020-01-20 | Oui | 2022-07-20 |
| posaconazole | 108193 | Posanol | Merck Canada Inc. | S.O. | 2007-03-26 | 2013-03-26 | Oui | 2015-09-26 |
| protéine de fusion facteur de coagulation IX humain recombiné-domaine fc | 163614 | Alprolix | Sanofi-Aventis Canada Inc. | S.O. | 2014-03-20 | 2020-03-20 | Oui | 2022-09-20 |
| protéine L1 recombinée du papillomavirus humain de type 11, de type 16, de type 18, de type 6 | 102682 | Gardasil | Merck Frosst Canada Ltd. | S.O. | 2006-07-10 | 2012-07-10 | Oui | 2015-01-10 |
| protéine NHBA hybride recombinante de Neisseria meningitidis du sérogroupe B, protéine NadA recombinante de Neisseria meningitidis du sérogroupe B, protéine fHbp hybride recombinante de Neisseria meningitidis du sérogroupe B, vésicules de membrane externe (Neisseria meningitidis group B souche NZ98/254) | 147275 | Bexsero | GlaxoSmithKline Inc. | S.O. | 2013-12-06 | 2019-12-06 | Oui | 2022-06-06 |
| raltégravir potassique | 113408 | Isentress | Merck Frosst Canada Ltd. | S.O. | 2007-11-27 | 2013-11-27 | Oui | 2016-05-27 |
| ramucirumab | 176810 | Cyramza | Eli Lilly Canada Inc. | S.O. | 2015-07-16 | 2021-07-16 | S.O | 2023-07-16 |
| ranibizumab | 110233 | Lucentis | Novartis Opthalmics, Novartis Pharmaceuticals | S.O. | 2007-06-26 | 2013-06-26 | S.O. | 2015-12-26 |
| recombinant virus du papillome humain de types 31, 33, 45, 52 et 58 | 170006 | Gardasil 9 | Merck Canada Inc. | S.O. | 2015-02-05 | 2021-02-05 | Oui | 2023-08-05 |
| regorafenib monohydrate | 157970 | Stivarga | Bayer Inc. | S.O. | 2013-03-11 | 2019-03-11 | Oui | 2021-09-11 |
| rémestemcel-L | 150026 | Prochymal | Osiris Therapeutics Inc. | S.O. | 2012-05-17 | 2018-05-17 | Oui | 2020-11-17 |
| rétapamuline | 109037 | Altargo | GlaxoSmithKline Inc. | S.O. | 2008-03-19 | 2014-03-19 | Oui | 2016-09-19 |
| rifaximine | 161256 | Zaxine | Salix Pharmaceuticals Inc. | S.O. | 2013-08-13 | 2019-08-13 | S.O. | 2021-08-13 |
| riociguat | 162761 | Adempas | Bayer Inc. | S.O. | 2013-09-19 | 2019-09-19 | S.O. | 2021-09-19 |
| rivaroxaban | 119111 | Xarelto | Bayer Healthcare | S.O. | 2008-09-15 | 2014-09-15 | S.O. | 2016-09-15 |
| roflumilast | 127683 | Daxas | Takeda Canada Inc. | S.O. | 2010-11-23 | 2016-11-23 | S.O. | 2018-11-23 |
| romidepsine | 152293 | Istodax | Celgene Inc. | S.O. | 2013-10-16 | 2019-10-16 | S.O. | 2021-10-16 |
| romiplostim | 117327 | Nplate | Amgen Canada Inc. | S.O. | 2009-02-19 | 2015-02-19 | Oui | 2017-08-19 |
| rotigotine | 145523 | Neupro | UCB Canada Inc. | S.O. | 2013-03-21 | 2019-03-21 | S.O. | 2021-03-21 |
| rufinamide | 139913 | Banzel | Eisai Limited | S.O. | 2011-06-22 | 2017-06-22 | Oui | 2019-12-22 |
| sécukinumab | 170732 | Cosentyx | Novartis Pharmaceuticals Canada Inc. | S.O. | 2015-02-27 | 2021-02-27 | Oui | 2023-08-27 |
| silodosine | 121740 | Rapaflo | Purdue Pharma | S.O. | 2011-01-11 | 2017-01-11 | S.O. | 2019-01-11 |
| siltuximab | 174291 | Sylvant | EUSA Pharma (UK) Limited | S.O. | 2014-12-03 | 2020-12-03 | S.O | 2022-12-03 |
| siméprévir | 164021 | Galexos | Janssen Inc. | S.O. | 2013-11-18 | 2019-11-18 | S.O. | 2021-11-18 |
| sitaxsentan sodique | 101934 | Thelin | Pfizer Canada Inc. | S.O. | 2007-05-30 | 2013-05-30 | S.O. | 2015-05-30 |
| sofosbuvir | 165043 | Sovaldi | Gilead Sciences Canada Inc. | Harvoni Epclusa Vosevi |
2013-12-13 | 2019-12-13 | S.O. | 2021-12-13 |
| sorafénib | 102070 | Nexavar | Bayer Inc. | S.O. | 2006-07-28 | 2012-07-28 | S.O. | 2014-07-28 |
| stiripentol | 142417 | Diacomit | Biocodex SA | S.O. | 2012-12-21 | 2018-12-21 | Oui | 2021-06-21 |
| succinate de desvenlafaxine | 115439 | Pristiq | Pfizer Canada Inc. | S.O. | 2009-02-04 | 2015-02-04 | Oui | 2017-08-04 |
| succinate de prucalopride | 141157 | Resotran | Janssen Inc. | S.O. | 2011-12-07 | 2017-12-07 | S.O. | 2019-12-07 |
| tafluprost | 165596 | Saflutan | Purdue Pharma | S.O. | 2014-05-26 | 2020-05-26 | S.O. | 2022-05-26 |
| taliglucérase alfa | 140854 | Elelyso | Pfizer Canada Inc. | S.O. | 2014-05-29 | 2020-05-29 | Oui | 2022-11-29 |
| téduglutide | 180223 | Revestive | Takeda Canada Inc. | S.O. | 2015-09-04 | 2021-09-04 | Oui | 2024-03-04 |
| télaprévir | 142482 | Incivek | Vertex Pharmaceuticals (Canada) Inc. | S.O. | 2011-08-16 | 2017-08-16 | S.O. | 2019-08-16 |
| telbivudine | 104469 | Sebivo | Novartis Pharmaceuticals Canada Inc. | S.O. | 2006-11-28 | 2012-11-28 | S.O. | 2014-11-28 |
| temsirolimus | 109201 | Torisel | Pfizer Canada Inc. | S.O. | 2007-12-21 | 2013-12-21 | Oui | 2016-06-21 |
| tériflunomide | 160646 | Aubagio | Genzyme Canada, une division de Sanofi-aventis Canada Inc. | S.O. | 2013-11-14 | 2019-11-14 | Oui | 2022-05-14 |
| tesamorelin | 131836 | Egrifta | Theratechnologies Inc. | S.O. | 2014-04-29 | 2020-04-29 | S.O. | 2022-04-29 |
| ticagrélor | 132218 | Brilinta | AstraZeneca Canada Incorporated | S.O. | 2011-05-30 | 2017-05-30 | S.O. | 2019-05-30 |
| tigecycline | 094870 | Tygacil | Pfizer Canada Inc. | S.O. | 2006-09-14 | 2012-09-14 | S.O. | 2014-09-14 |
| tocilizumab | 121089 | Actemra | Hoffmann-La Roche Ltd. | S.O. | 2010-04-30 | 2016-04-30 | Oui | 2018-10-30 |
| tofacitinib | 154642 | Xeljanz | Pfizer Canada Inc. | S.O. | 2014-04-17 | 2020-04-17 | Oui | 2022-10-17 |
| tolvaptan | 139413 | Samsca | Otsuka Pharmaceutical Co. Ltd. | Jinarc | 2011-07-25 | 2017-07-25 | S.O. | 2019-07-25 |
| trabectedine | 124729 | Yondelis | Janssen Inc. | S.O. | 2010-05-13 | 2016-05-13 | S.O. | 2018-05-13 |
| trametinib | 157665 | Mekinist | Novartis Pharmaceuticals Canada Inc. | S.O. | 2013-07-18 | 2019-07-18 | S.O. | 2021-07-18 |
| turoctocog alfa | 170796 | Zonovate | Novo Nordisk Canada Inc. | S.O. | 2014-12-08 | 2020-12-08 | Oui | 2023-06-08 |
| ustékinumab | 114272 | Stelara | Janssen Inc. | S.O. | 2008-12-12 | 2014-12-12 | S.O. | 2016-12-12 |
| vaccin antirotavirus (souche RIX441), vivant, oral, atténué (humain) | 109624 | Rotarix | GlaxoSmithKline Inc. | S.O. | 2007-10-09 | 2013-10-09 | Oui | 2016-04-09 |
| vaccin antirotavirus, vivant, oral, de type G1, de type G2, de type G3, de type G4, de type P1(8) (humain) | 100399 | Rotateq | Merck Frosst Canada Ltd. | S.O. | 2006-08-01 | 2012-08-01 | Oui | 2015-02-01 |
| vandétanib | 126822 | Caprelsa | Genzyme Canada, une division de Sanofi-aventis Canada Inc. | S.O. | 2012-01-12 | 2018-01-12 | S.O. | 2020-01-12 |
| varenicline tartrate | 104007 | Champix | Pfizer Canada Inc. | S.O. | 2007-01-24 | 2013-01-24 | Oui | 2015-07-24 |
| vélaglucérase alfa | 132604 | Vpriv | Shire Human Genetic Therapies, Inc. | S.O. | 2010-10-01 | 2016-10-01 | Oui | 2019-04-01 |
| vémurafénib | 148693 | Zelboraf | Hoffmann-La Roche Ltd. | S.O. | 2012-02-15 | 2018-02-15 | S.O. | 2020-02-15 |
| vilantérol trifénatate | 157301 | Breo Ellipta | GlaxoSmithKline Inc. | Anora Ellipta Trelegy Ellipta |
2013-07-03 | 2019-07-03 | Oui | 2022-01-03 |
| virus de l'influenza de type A (H1N1), virus de l'influenza de type A (H3N2), virus de l'influenza de type B | 129379 | FluMist | AstraZeneca Canada Incorporated | FluMist Quadrivalent | 2010-06-22 | 2016-06-22 | Oui | 2018-12-22 |
| virus modifié de la vaccine (ankara-bavarian nordic) | 144762 | Imvamune | Bavarian Nordic A/S | S.O. | 2013-11-21 | 2019-11-21 | S.O. | 2021-11-21 |
| vismodegib | 154608 | Erivedge | Hoffmann-La Roche Ltd. | S.O. | 2013-07-12 | 2019-07-12 | S.O. | 2021-07-12 |
| vorinostat | 104562 | Zolinza | Merck Frosst Canada Ltd. | S.O. | 2009-06-11 | 2015-06-11 | S.O. | 2017-06-11 |
| zucapsaicine | 121952 | Zuacta | Sanofi-aventis Canada Inc. | S.O. | 2010-07-15 | 2016-07-15 | S.O. | 2018-07-15 |
| Ingrédient(s) médicinal(aux) Footnote 1 |
Nº de la présentation | Drogue innovante | Nom du fabricant | Drogue(s) contenant l'ingrédient médicinal / variante | Date de l'avis de conformité aaaa-mm-jj |
Date de la période de "non-dépôt" de 6 ans | Fin de la période de protection des données |
|---|---|---|---|---|---|---|---|
| acetate de gonadoréline[6-D-Phe] | 256977 | Gonavet | Modern Veterinary Therapeutics LL | S.O. | 2022-10-20 | 2028-10-20 | 2030-10-20 |
| bédinvetmab | 237723 | Librela | Zoetis Canada Inc | S.O. | 2021-02-01 | 2027-02-01 | 2029-02-01 |
| chlorhydrate de bupivacaÏne | 254222 | Tri-Solfen | Dechra Ltd | S.O. | 2022-06-21 | 2028-06-21 | 2030-06-21 |
| bésylate ď'amlodipine | 218786 | Amodip Flavoured Tablets | Ceva Animal Health Inc | S.O. | 2020-03-25 | 2026-03-25 | 2028-03-25 |
| chlorhydrate de methadone | 226217 | Comfortan | chlorhydrate de methadon | S.O. | 2020-02-25 | 2026-02-25 | 2028-02-25 |
| chlorhydrate de vatinoxan | 256567 | Zenalpha | Dechra Veterinary Products Inc. | S.O. | 2023-05-01 | 2029-05-01 | 2031-05-01 |
| ciclésonide | 200882 | Aservo Equihaler | Boehringer Ingelheim Animal Health Canada Inc | S.O. | 2020-04-30 | 2026-04-30 | 2028-04-30 |
| derquantel | 184844 | Startect | Zoetis Canada Inc | S.O. | 2016-04-27 | 2022-04-27 | 2024-04-27 |
| frunévetmab | 242879 | Solensia | Zoetis Canada Inc | S.O. | 2021-07-27 | 2027-07-27 | 2029-07-27 |
| grapiprant | 211760 | Galliprant | Elanco Canada Limite | S.O. | 2019-01-08 | 2025-01-08 | 2027-01-08 |
| isoeugénol | 252779 | Aqui-S | AQUI-S New Zealand Ltd. | S.O. | 2023-07-31 | 2029-07-31 | 2031-07-31 |
| lotilaner | 193712 | Credelio | Elanco Canada Limite | Credelio Plus Credelio Cat |
2017-12-29 | 2023-12-29 | 2025-12-29 |
| lubabégron | 166199 | Experior 10 | Elanco Canada Limite | Experior 50 | 2018-11-07 | 2024-11-07 | 2026-11-07 |
| midazolam | 230770 | Dormazolam | Dechra Regulatory B | S.O. | 2021-06-29 | 2027-06-29 | 2029-06-29 |
| mirtazapine | 232197 | Mirataz | Dechra Ltd | S.O. | 2020-09-08 | 2026-09-08 | 2028-09-08 |
| monohydrate de L-proline de vélagliflozine | 265785 | Senvelgo | Boehringer Ingelheim Animal Health Canada Inc. | S.O. | 2023-11-28 | 2029-11-28 | 2031-11-28 |
| péforéline | 190986 | Maprelin XP-10 | Modern Veterinary Therapeutics LL | S.O. | 2017-06-19 | 2023-06-19 | 2025-06-19 |
| spironolactone | 263787 | Cardalis | Ceva Animal Health Inc. | S.O. | 2023-10-11 | 2029-10-11 | 2031-10-11 |
| tétracosactide | 228462 | Cosacthen | Dechra Ltd | S.O. | 2020-04-27 | 2026-04-27 | 2028-04-27 |
| Ingrédient(s) médicinal(aux)Footnote 1 |
Nº de la présentation | Drogue innovante | Nom du fabricant | Drogue(s) contenant l'ingrédient médicinal / variante | Date de l'avis de conformité aaaa-mm-jj |
Date de la période de "non-dépôt" de 6 ans | Fin de la période de protection des données |
|---|---|---|---|---|---|---|---|
| acétaminophène | 110139 | Pracetam 20% O.S. | Ceva Animal Health In | S.O. | 2009-03-05 | 2015-03-05 | 2017-03-05 |
| acétate de triptoréline | 161303 | Ovugel | United-AH II, LL | S.O. | 2014-04-25 | 2020-04-25 | 2022-04-25 |
| afoxolaner | 163768 | Nexgard | Boehringer Ingelheim Animal Health Canada Inc | Nexgard Spectra Nexgard Combo |
2014-07-08 | 2020-07-08 | 2022-07-08 |
| avilamycine | 156949 | Surmax 100 Premix | Elanco Canada Limite | Surmax 200 Premix | 2020-02-18 | 2020-02-18 | 2020-02-18 |
| benzoate d'émamectine | 109976 | Slice | Intervet Canada Corp | S.O. | 2009-06-29 | 2015-06-29 | 2017-06-29 |
| chlorhydrate de buprénorphine | 126077 | Vetergesic Multidose | Sogeval UK Limite | S.O. | 2010-02-03 | 2016-02-03 | 2018-02-03 |
| céfovécine sodique | 110061 | Convenia | Zoetis Canada Inc | S.O. | 2007-05-30 | 2013-05-30 | 2015-05-30 |
| cefpodoxime proxétil | 149164 | Simplicef | Zoetis Canada Inc | S.O. | 2012-12-06 | 2018-12-06 | 2020-12-06 |
| chlorhydrate de fluoxétine | 109825 / 109826 / 110429 | Reconcile | Elanco, Division Eli Lilly Canada Inc. | S.O. | 2008-03-28 | 2014-03-28 | 2016-03-28 |
| chlorhydrate d'imidapril | 110445 / 110450 / 110476 | Prilium | Vétoquinol NA Inc | S.O. | 2007-07-12 | 2013-07-12 | 2015-07-12 |
| chlorhydrate de zilpatérol | 110019 | Zilmax | Intervet Canada Ltd. | S.O. | 2009-03-18 | 2015-03-18 | 2017-03-18 |
| citrate de maropitant | 110342 / 110344 / 110347 / 110348 | Cerenia | Zoetis Canada Inc | S.O. | 2007-09-20 | 2013-09-20 | 2015-09-20 |
| clodronate disodique tetrahydrate | 172789 | Osphos Injection | Dechra Ltd | S.O. | 2015-05-06 | 2021-05-06 | 2023-05-06 |
| closantel sodique | 180678 | Flukiver | Elanco Division Eli Lilly Canada Inc | S.O. | 2015-11-24 | 2021-11-24 | 2023-11-24 |
| conjugué protéine-analogue du facteur de libération de la gonadotrophine | 140525 | Improvest | Zoetis Canada Inc. | S.O. | 2011-06-22 | 2017-06-22 | 2019-06-22 |
| dibotermine alfa (rhBMP-2) | 148153 | Truscient | Zoetis Canada Inc | S.O. | 2012-11-20 | 2018-11-20 | 2020-11-20 |
| dirlotapide | 110110 | Slentrol | Zoetis Canada Inc | S.O. | 2008-08-14 | 2014-08-14 | 2016-08-14 |
| émodepside | 112103 / 112106 / 112107 | Profender | Bayer Healthcare, Animal Health Divisio | S.O. | 2008-08-28 | 2014-08-28 | 2016-08-28 |
| itraconazole | 109769 | Itrafungol | Elanco, Division Eli Lilly Canada Inc | S.O. | 2008-09-23 | 2014-09-23 | 2016-09-23 |
| maléate d'oclacitinib | 159090 | Apoquel | Zoetis Canada Inc | S.O. | 2014-07-15 | 2020-07-15 | 2022-07-15 |
| firocoxib | 110661 / 110379 | Previcox | Merial Canada Inc | S.O. | 2007-09-28 | 2013-09-28 | 2015-09-28 |
| fluralaner | 166320 | Bravecto | Intervet Canada Corp | Vitrecto Bravecto One |
2014-05-23 | 2020-05-23 | 2022-05-23 |
| furoate de mométasone monohydraté | 110289 | Mometamax | Intervet Canada Corp | S.O. | 2010-02-22 | 2016-02-22 | 2018-02-22 |
| ibafloxacine | 110655 / 110657 | Ibaflin gel | Intervet Canada Ltd | S.O. | 2008-01-15 | 2014-01-15 | 2016-01-15 |
| insuline humaine (recombinant) | 150211 | Prozinc | Boehringer Ingelheim Animal Health Canad | S.O. | 2013-04-24 | 2019-04-24 | 2021-04-24 |
| gamithromycin | 125823 | Zactran | Merial Canada Inc | S.O. | 2010-03-29 | 2016-03-29 | 2018-03-29 |
| mésylate de pergolide | 158770 | Prascend | Boehringer Ingelheim Animal Health Canada Inc | S.O. | 2013-09-05 | 2019-09-05 | 2021-09-05 |
| mitratapide | 111600 | Yarvitan | Janssen Pharmaceutica N. | S.O. | 2009-02-20 | 2015-02-20 | 2017-02-20 |
| monohydrate de céphalexine | 126970 | Vetolexin | Vétoquinol N.- A Inc | Cefaseptin | 2010-06-24 | 2016-06-24 | 2018-06-24 |
| pegbovigrastim | 148171 | Imrestor | Elanco Division Eli Lilly Canada Inc | S.O. | 2016-03-09 | 2024-03-09 | 2024-03-09 |
| perméthrine | 133818 | Oridermyl | Vétoquinol N.- A Inc | S.O. | 2011-02-18 | 2017-02-18 | 2019-02-18 |
| phénobarbital | 142445 | Epiphen | Vétoquinol N.- A Inc | S.O. | 2012-04-04 | 2018-04-04 | 2020-04-04 |
| phosphate de tocénanib | 123643 | Palladia | Zoetis Canada Inc | S.O. | 2009-12-01 | 2015-12-01 | 2017-12-01 |
| pradofloxacin | 161227 | Veraflox | Elanco Canada Limite | S.O. | 2015-01-29 | 2021-01-29 | 2023-01-29 |
| ramipril | 110296 / 110297 / 110298 | Vasotop | Intervet Canada Ltd | S.O. | 2008-09-05 | 2014-09-05 | 2016-09-05 |
| robénacoxib | 128703 | Onsior | Elanco Canada Limite | S.O. | 2011-10-03 | 2017-10-03 | 2019-10-03 |
| sarolaner | 177679 | Simparica | Zoetis Canada Inc. | Revolution Plus Simparica Trio |
2016-02-11 | 2022-02-11 | 2024-02-11 |
| sévoflurane | 110109 | Sevoflo | Zoetis Canada Inc | S.O. | 2008-03-28 | 2014-03-28 | 2016-03-28 |
| spinosad | 112198 / 112199 / 112202 / 112203 / 112204 | Comfortis | Elanco, Division Eli Lilly Canada Inc | Trifexis | 2009-08-24 | 2015-08-24 | 2017-08-24 |
| telmisartan | 158760 | Semintra | Boehringer Ingelheim Animal Health Canada Inc | S.O. | 2013-12-12 | 2019-12-12 | 2021-12-12 |
| tépoxaline | 109950 / 109956 / 109963 | Zubrin | Schering Plough Canada Inc | S.O. | 2007-10-01 | 2013-10-01 | 2015-10-01 |
| terbinafine | 170344 | Osurnia | Dechra Ltd. | S.O. | 2015-03-26 | 2021-03-26 | 2023-03-26 |
| thiamazol | 125706 | Felimazole | Dechra Ltd | S.O. | 2009-08-25 | 2015-08-25 | 2017-08-25 |
| tildipirosine | 148052 | Zuprevo | Intervet Canada Corp | S.O. | 2012-06-13 | 2018-06-13 | 2020-06-13 |
| tiludronate de disodium | 171467 | Tildren | CEVA Animal Healt | S.O. | 2014-12-22 | 2020-12-22 | 2022-12-22 |
| toltrazuril | 122525 | Baycox | Bayer Inc., Bayer Healthcare Animal Health Divisio | S.O. | 2010-08-20 | 2016-08-20 | 2018-08-20 |
| tulathromycine | 112161 | Draxxin | Pfizer Canada Inc., Animal Health Grou | S.O. | 2006-08-31 | 2012-08-31 | 2014-08-31 |
Contexte
Le registre des drogues innovantes est tenu en vertu de l'article C.08.004.1(9) du Règlement sur les aliments et drogues. Le registre mentionne les drogues qui sont admissibles à la protection des données. En vertu du paragraphe C.08.004.1(3), un fabricant ultérieur qui demande la délivrance d'un avis de conformité sur la base d'une comparaison directe ou indirecte entre la nouvelle drogue et une drogue innovante ne peut pas déposer de présentation avant l'expiration d'un délai de six ans suivant la date à laquelle le premier avis de conformité a été délivré pour la nouvelle drogue innovante. Par ailleurs, l'avis de conformité ne peut pas être délivré avant l'expiration d'un délai de huit ans suivant la date à laquelle le premier avis de conformité a été délivré à l'innovateur.
Le format du registre des drogues innovantes est en tableau électronique qui sera mis à jour chaque semaine. Il comporte la nomenclature des ingrédients médicinaux non déjà approuvés dans une drogue par le ministre et qui ne constituent pas une variante d'un ingrédient médicinal déjà approuvé, classée par ordre alphabétique. Veuillez noter que les drogues pourraient comprendre d'autres ingrédients médicinaux. Le registre a été restructuré dans l'été 2016 afin d'améliorer la clarté des informations concernant l'ingrédient médicinal, la marque, et le fabricant de chacune des drogues innovantes.
Pour plus de renseignements :
Pour obtenir des renseignements sur les options de traitement, les médicaments possibles et leurs usages, les maladies, les effets secondaires ou les interactions médicamenteuses, veuillez-vous adresser à votre professionnel de la santé (par exemple, médecin, pharmacien, etc.). Nous n'offrons pas de conseils médicaux sur l'usage des produits qui figurent dans la base de données.
Pour tout commentaire ou question, veuillez communiquer avec le :
Bureau des médicaments brevetés et liaison
Courriel : opml-bmbl@hc-sc.gc.ca
Téléphone : 613-941-7281
Détails de la page
- Date de modification :